Structured Review

Millipore igg2
Detection of <t>IgG</t> subclasses directed against the 30-kDa Ag. Sera from patients with active TB were analyzed by ELISA for specific IgG subclass reactivity to 30-kDa Ag. Results are presented as mean OD units ± SE.
Igg2, supplied by Millipore, used in various techniques. Bioz Stars score: 99/100, based on 702 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/igg2/product/Millipore
Average 99 stars, based on 702 article reviews
Price from $9.99 to $1999.99
igg2 - by Bioz Stars, 2020-08
99/100 stars

Images

1) Product Images from "Cytokine Profiles for Peripheral Blood Lymphocytes from Patients with Active Pulmonary Tuberculosis and Healthy Household Contacts in Response to the 30-Kilodalton Antigen of Mycobacterium tuberculosis"

Article Title: Cytokine Profiles for Peripheral Blood Lymphocytes from Patients with Active Pulmonary Tuberculosis and Healthy Household Contacts in Response to the 30-Kilodalton Antigen of Mycobacterium tuberculosis

Journal: Infection and Immunity

doi:

Detection of IgG subclasses directed against the 30-kDa Ag. Sera from patients with active TB were analyzed by ELISA for specific IgG subclass reactivity to 30-kDa Ag. Results are presented as mean OD units ± SE.
Figure Legend Snippet: Detection of IgG subclasses directed against the 30-kDa Ag. Sera from patients with active TB were analyzed by ELISA for specific IgG subclass reactivity to 30-kDa Ag. Results are presented as mean OD units ± SE.

Techniques Used: Enzyme-linked Immunosorbent Assay

2) Product Images from "Profiling of microorganism-binding serum antibody specificities in professional athletes"

Article Title: Profiling of microorganism-binding serum antibody specificities in professional athletes

Journal: PLoS ONE

doi: 10.1371/journal.pone.0203665

Graphic representation showing correlation coefficients obtained by correlating the string of reactivity of serum IgG ofdifferent individuals to different microorganism, obtained in ELISA, at steady state. A) Professional athletes; B) Control group. Red colour–Pearson product-moment correlation coefficient, r = 1, Blue– r = -1.
Figure Legend Snippet: Graphic representation showing correlation coefficients obtained by correlating the string of reactivity of serum IgG ofdifferent individuals to different microorganism, obtained in ELISA, at steady state. A) Professional athletes; B) Control group. Red colour–Pearson product-moment correlation coefficient, r = 1, Blue– r = -1.

Techniques Used: Enzyme-linked Immunosorbent Assay

Graphic representation showing correlation coefficients obtained by correlating the string of reactivity of serumtotal IgG and total IgA with IgG subclasses, for different microorganisms in professional athletes. A) Escherichia coli ATCC25922; B) Candida albicans ATCC 10259; C) Lactobacillus plantarum WCFS1; D) Salmonella typhimurium 2865; E) Lactobacillusrhamnosus LGG, F) LPS from E . coli O55:B5.
Figure Legend Snippet: Graphic representation showing correlation coefficients obtained by correlating the string of reactivity of serumtotal IgG and total IgA with IgG subclasses, for different microorganisms in professional athletes. A) Escherichia coli ATCC25922; B) Candida albicans ATCC 10259; C) Lactobacillus plantarum WCFS1; D) Salmonella typhimurium 2865; E) Lactobacillusrhamnosus LGG, F) LPS from E . coli O55:B5.

Techniques Used:

Analysis of reactivity of serial dilutions of serum IgG in A) professional athletes; B) control group, and of serum IgA in C) professional athletes; D) control group to different microorganisms. Red colour– E . coli ATCC25922; black - C . albicans ATCC 10259; turquoise– L . plantarum WCFS1; green– S . typhimurium 2865; blue— L . rhamnosus LGG, violet—LPS from E . coli 055:B5.
Figure Legend Snippet: Analysis of reactivity of serial dilutions of serum IgG in A) professional athletes; B) control group, and of serum IgA in C) professional athletes; D) control group to different microorganisms. Red colour– E . coli ATCC25922; black - C . albicans ATCC 10259; turquoise– L . plantarum WCFS1; green– S . typhimurium 2865; blue— L . rhamnosus LGG, violet—LPS from E . coli 055:B5.

Techniques Used:

The strings of reactivities (apsorbance) of IgG and IgA to bacteria from different individuals were correlated, and the Pearson product-moment correlation coefficientswereplotted for individual bacteria. Red colour- Professional athletes PA; Green colour–Control.
Figure Legend Snippet: The strings of reactivities (apsorbance) of IgG and IgA to bacteria from different individuals were correlated, and the Pearson product-moment correlation coefficientswereplotted for individual bacteria. Red colour- Professional athletes PA; Green colour–Control.

Techniques Used:

3) Product Images from "Association of immunoglobulin G4 and free light chain with idiopathic pleural effusion"

Article Title: Association of immunoglobulin G4 and free light chain with idiopathic pleural effusion

Journal: Clinical and Experimental Immunology

doi: 10.1111/cei.12999

Correlation of the effusion κ/λ free L chains (FLC) ratio with immunoglobulin (Ig)G4 + plasma cell counts (a) and IgG4 + /IgG + plasma cell ratio (b) in the pleura of patients in the IgG4 + group. *One‐tailed P ‐value.
Figure Legend Snippet: Correlation of the effusion κ/λ free L chains (FLC) ratio with immunoglobulin (Ig)G4 + plasma cell counts (a) and IgG4 + /IgG + plasma cell ratio (b) in the pleura of patients in the IgG4 + group. *One‐tailed P ‐value.

Techniques Used: One-tailed Test

Receiver operating characteristic (ROC) analysis on diagnostic utility of immunoglobulin (Ig)G4 and κ/λ ratio for distinguishing patients between the IgG4 − and IgG + groups. Cut‐off value for κ/λ ratio, 1·42; sensitivity, 0·87; specificity, 0·83. Area under the curve (AUC), 0·88; 95% confidence interval (CI) for the AUC, 0·74 – 1·00. Cut‐off value for IgG4/IgG ratio, 2·75%; sensitivity, 0·75; specificity, 0·74; AUC, 0·80; 95% CI for the AUC, 0·66–0·94.
Figure Legend Snippet: Receiver operating characteristic (ROC) analysis on diagnostic utility of immunoglobulin (Ig)G4 and κ/λ ratio for distinguishing patients between the IgG4 − and IgG + groups. Cut‐off value for κ/λ ratio, 1·42; sensitivity, 0·87; specificity, 0·83. Area under the curve (AUC), 0·88; 95% confidence interval (CI) for the AUC, 0·74 – 1·00. Cut‐off value for IgG4/IgG ratio, 2·75%; sensitivity, 0·75; specificity, 0·74; AUC, 0·80; 95% CI for the AUC, 0·66–0·94.

Techniques Used: Diagnostic Assay

Comparison of pleural fluid levels of the κ and λ free L chains (FLC) (a,b) and κ/λ ratio (c). Median and interquartile ranges are shown. (−), Immunoglobulin (Ig)G4 − group; (+), IgG4 + group.
Figure Legend Snippet: Comparison of pleural fluid levels of the κ and λ free L chains (FLC) (a,b) and κ/λ ratio (c). Median and interquartile ranges are shown. (−), Immunoglobulin (Ig)G4 − group; (+), IgG4 + group.

Techniques Used:

Comparison of pleural fluid levels of immunoglobulins between the immunoglobulin (Ig)G4 − and IgG4 + groups. (−), IgG4 − group; (+), IgG4 + group. Median and interquartile ranges are shown.
Figure Legend Snippet: Comparison of pleural fluid levels of immunoglobulins between the immunoglobulin (Ig)G4 − and IgG4 + groups. (−), IgG4 − group; (+), IgG4 + group. Median and interquartile ranges are shown.

Techniques Used:

Analysis of the clonality of the effusion immunoglobulin (Ig)G4 antibodies of patients in the IgG4 + group by two‐dimensional electrophoresis (2‐DE). Control IgG4 κ myeloma protein from Sigma (cat no. I4639) (a –c). Effusion IgG4 antibodies of representative cases with abnormal IgG4 levels (d–i). The H and L chains were probed with anti‐IgG4‐Fc (left), anti‐κ chain (middle) and anti‐λ chain (right) antibodies.
Figure Legend Snippet: Analysis of the clonality of the effusion immunoglobulin (Ig)G4 antibodies of patients in the IgG4 + group by two‐dimensional electrophoresis (2‐DE). Control IgG4 κ myeloma protein from Sigma (cat no. I4639) (a –c). Effusion IgG4 antibodies of representative cases with abnormal IgG4 levels (d–i). The H and L chains were probed with anti‐IgG4‐Fc (left), anti‐κ chain (middle) and anti‐λ chain (right) antibodies.

Techniques Used: Electrophoresis

4) Product Images from "Unilateral Sensorimotor Cortex Lesions in Adult Rats Facilitate Motor Skill Learning with the “Unaffected” Forelimb and Training-Induced Dendritic Structural Plasticity in the Motor Cortex"

Article Title: Unilateral Sensorimotor Cortex Lesions in Adult Rats Facilitate Motor Skill Learning with the “Unaffected” Forelimb and Training-Induced Dendritic Structural Plasticity in the Motor Cortex

Journal: The Journal of Neuroscience

doi: 10.1523/JNEUROSCI.22-19-08597.2002

Reconstructions of the extent and placement of unilateral lesions of the forelimb region of the sensorimotor cortex (FLsmc) ( A , C – E ) and regions of quantification of MAP2 immunoreactive processes in the motor cortex [lateral agranular region ( AGl )] and granular insular cortex ( GI ) opposite the lesion ( B ). The regions outlined in black in A and C – E indicate the largest extent of all lesions combined, whereas gray areas indicate the damaged tissue common to all lesions in that group. Numbers in B and E are approximate coordinates in millimeters relative to bregma.
Figure Legend Snippet: Reconstructions of the extent and placement of unilateral lesions of the forelimb region of the sensorimotor cortex (FLsmc) ( A , C – E ) and regions of quantification of MAP2 immunoreactive processes in the motor cortex [lateral agranular region ( AGl )] and granular insular cortex ( GI ) opposite the lesion ( B ). The regions outlined in black in A and C – E indicate the largest extent of all lesions combined, whereas gray areas indicate the damaged tissue common to all lesions in that group. Numbers in B and E are approximate coordinates in millimeters relative to bregma.

Techniques Used:

The surface density of MAP2-immunoreactive dendrites in layer V ( A ) and layer II/III ( B ) of the motor cortex opposite the lesion and/or trained limb. In layer V, increases in MAP2-IR were especially evident after unilateral lesions, although there were also significant increases after reach training in intact animals ( Sham + Training ). Reach training after lesions ( Lesion + Training ) produced further increases in MAP2-IR dendrites than that found after lesions alone or training alone. In Layer II/III ( B ), increases in the surface density of MAP2-IR dendrites were greatest in intact animals receiving unilateral reach training, whereas lesions alone produced a smaller but significant increase in comparison with Sham + No-Training. Reach training after the lesions increased MAP2-IR in comparison with lesions alone, but not in comparison with training alone in layer II/III. Data are means ± SEM. * p
Figure Legend Snippet: The surface density of MAP2-immunoreactive dendrites in layer V ( A ) and layer II/III ( B ) of the motor cortex opposite the lesion and/or trained limb. In layer V, increases in MAP2-IR were especially evident after unilateral lesions, although there were also significant increases after reach training in intact animals ( Sham + Training ). Reach training after lesions ( Lesion + Training ) produced further increases in MAP2-IR dendrites than that found after lesions alone or training alone. In Layer II/III ( B ), increases in the surface density of MAP2-IR dendrites were greatest in intact animals receiving unilateral reach training, whereas lesions alone produced a smaller but significant increase in comparison with Sham + No-Training. Reach training after the lesions increased MAP2-IR in comparison with lesions alone, but not in comparison with training alone in layer II/III. Data are means ± SEM. * p

Techniques Used: Produced

5) Product Images from "Evaluation of Wuchereria bancrofti GST as a Vaccine Candidate for Lymphatic Filariasis"

Article Title: Evaluation of Wuchereria bancrofti GST as a Vaccine Candidate for Lymphatic Filariasis

Journal: PLoS Neglected Tropical Diseases

doi: 10.1371/journal.pntd.0000457

Subclass specific anti-WbGST IgG antibodies in the sera of mice immunized with rWbGST protein. Subclass analysis was performed using a mouse antibody isotyping ELISA kit. The bars represent the mean O.D.±SD at 405 nm of five mice per group.
Figure Legend Snippet: Subclass specific anti-WbGST IgG antibodies in the sera of mice immunized with rWbGST protein. Subclass analysis was performed using a mouse antibody isotyping ELISA kit. The bars represent the mean O.D.±SD at 405 nm of five mice per group.

Techniques Used: Mouse Assay, Enzyme-linked Immunosorbent Assay

Human immune responses to WbGST. A. Immunoreactivity of rWbGST with sera from different clinical groups of bancroftian filariasis. Approximately 1 µg of rWbGST was resolved on 15% SDS-PAGE, transferred to nitrocellulose membrane and blots were probed with pooled sera from MF, CP, EN or NEN individuals. Results showed strong immunoreactivity with pooled EN sera followed by CP and MF but no reactivity was detected with control NEN sera. Data is representative of one of three experiments using the same sera samples. B. Humoral immune response to rWbGST in human subjects. Total IgG levels against rWbGST in various clinical groups were evaluated by ELISA. Each data point represents single individual absorbance from the four different groups. Horizontal lines represent geometric mean value of EN (43), Mf (45), CP (45) and NEN (39) samples respectively. C. WbGST-specific IgG subclasses in the sera from different clinical groups. Isotype of anti-WbGST IgG antibodies in the sera from various groups of human subjects (EN, MF, CP, TPE and NEN) were evaluated using an isotype-specific ELISA. Data presented is mean±SD value from EN (43), Mf (45), CP (45) and NEN (39). * Significant (p
Figure Legend Snippet: Human immune responses to WbGST. A. Immunoreactivity of rWbGST with sera from different clinical groups of bancroftian filariasis. Approximately 1 µg of rWbGST was resolved on 15% SDS-PAGE, transferred to nitrocellulose membrane and blots were probed with pooled sera from MF, CP, EN or NEN individuals. Results showed strong immunoreactivity with pooled EN sera followed by CP and MF but no reactivity was detected with control NEN sera. Data is representative of one of three experiments using the same sera samples. B. Humoral immune response to rWbGST in human subjects. Total IgG levels against rWbGST in various clinical groups were evaluated by ELISA. Each data point represents single individual absorbance from the four different groups. Horizontal lines represent geometric mean value of EN (43), Mf (45), CP (45) and NEN (39) samples respectively. C. WbGST-specific IgG subclasses in the sera from different clinical groups. Isotype of anti-WbGST IgG antibodies in the sera from various groups of human subjects (EN, MF, CP, TPE and NEN) were evaluated using an isotype-specific ELISA. Data presented is mean±SD value from EN (43), Mf (45), CP (45) and NEN (39). * Significant (p

Techniques Used: SDS Page, Enzyme-linked Immunosorbent Assay

6) Product Images from "Transplanted cord blood-derived endothelial precursor cells augment postnatal neovascularization"

Article Title: Transplanted cord blood-derived endothelial precursor cells augment postnatal neovascularization

Journal: Journal of Clinical Investigation

doi:

AT cells had EC-like functions and expressed cell surface markers in vitro. At day 7 of culture ( a ) AT cells took up DiI-ac-LDL. ( b ) AT cells were positive for endothelial constitutive NO synthase (ecNOS) immunostaining. ( c and d ) Incubating AT cells with DAF-2 DA, a NO-specific fluorescence indicator, showed that hVEGF 165 (50 ng/mL) ( d ), but not saline ( c ), induced NO release from AT cells. Bars, 50 μm in c and d . ( e ) Flow cytometric analyses of AT cells at day 7 of culture ( n = 8). Horizontal bars indicate positive antigen gates as determined by an isotype-matched IgG control study. AT cells were positive for KDR (52 ± 5%), VE-cadherin (62 ± 2%), CD34 (62 ± 7%), and CD31 (57 ± 9%), but not for CD45 (7 ± 3%). Data are percentage of positive cells.
Figure Legend Snippet: AT cells had EC-like functions and expressed cell surface markers in vitro. At day 7 of culture ( a ) AT cells took up DiI-ac-LDL. ( b ) AT cells were positive for endothelial constitutive NO synthase (ecNOS) immunostaining. ( c and d ) Incubating AT cells with DAF-2 DA, a NO-specific fluorescence indicator, showed that hVEGF 165 (50 ng/mL) ( d ), but not saline ( c ), induced NO release from AT cells. Bars, 50 μm in c and d . ( e ) Flow cytometric analyses of AT cells at day 7 of culture ( n = 8). Horizontal bars indicate positive antigen gates as determined by an isotype-matched IgG control study. AT cells were positive for KDR (52 ± 5%), VE-cadherin (62 ± 2%), CD34 (62 ± 7%), and CD31 (57 ± 9%), but not for CD45 (7 ± 3%). Data are percentage of positive cells.

Techniques Used: In Vitro, Immunostaining, Fluorescence, Flow Cytometry

7) Product Images from "Is peanut causing food allergy in Cuba? Preliminary assessment of allergic sensitization and IgE specificity profile to peanut allergens in Cuban allergic patients"

Article Title: Is peanut causing food allergy in Cuba? Preliminary assessment of allergic sensitization and IgE specificity profile to peanut allergens in Cuban allergic patients

Journal: The World Allergy Organization Journal

doi: 10.1186/s40413-017-0156-1

Western Blotting of roasted peanut extracts: a : IgE binding profile, b : IgG4 binding profile. MWM: Molecular Weight markers. Lanes 1: HSA 0.5% as negative control, Lanes 2 to 19, 21, 23 to 25 and 27, allergic adults, Lanes 20, 22 and 26 allergic children: Lanes 28 and 29: SDS-PAGE Coomassie stained gels of raw and roasted peanut extracts, respectively
Figure Legend Snippet: Western Blotting of roasted peanut extracts: a : IgE binding profile, b : IgG4 binding profile. MWM: Molecular Weight markers. Lanes 1: HSA 0.5% as negative control, Lanes 2 to 19, 21, 23 to 25 and 27, allergic adults, Lanes 20, 22 and 26 allergic children: Lanes 28 and 29: SDS-PAGE Coomassie stained gels of raw and roasted peanut extracts, respectively

Techniques Used: Western Blot, Binding Assay, Molecular Weight, Negative Control, SDS Page, Staining

8) Product Images from "The in Vitro Antigenicity of Plasmodium vivax Rhoptry Neck Protein 2 (PvRON2) B- and T-Epitopes Selected by HLA-DRB1 Binding Profile"

Article Title: The in Vitro Antigenicity of Plasmodium vivax Rhoptry Neck Protein 2 (PvRON2) B- and T-Epitopes Selected by HLA-DRB1 Binding Profile

Journal: Frontiers in Cellular and Infection Microbiology

doi: 10.3389/fcimb.2018.00156

Evaluating IgG subclass response to the 39041 epitope ( n = 6). The Kruskal-Wallis test was used for analyzing differences between each IgG subclass response in P. vivax -exposed individuals' samples. ** p
Figure Legend Snippet: Evaluating IgG subclass response to the 39041 epitope ( n = 6). The Kruskal-Wallis test was used for analyzing differences between each IgG subclass response in P. vivax -exposed individuals' samples. ** p

Techniques Used:

IgG antibody response to Pv RON2 B epitopes by endemic area. Significant differences (calculated by Mann-Whitney test) between samples from Colombia's Chocó ( n = 13) and Córdoba ( n = 17) departments are shown. The dashed line indicates the cut-off point for seropositive samples. * p
Figure Legend Snippet: IgG antibody response to Pv RON2 B epitopes by endemic area. Significant differences (calculated by Mann-Whitney test) between samples from Colombia's Chocó ( n = 13) and Córdoba ( n = 17) departments are shown. The dashed line indicates the cut-off point for seropositive samples. * p

Techniques Used: MANN-WHITNEY

IgG antibody response against four Pv RON2 B-cell epitopes ( n = 30). Seropositive samples were those above the cut-off point (0.218, dotted line), calculated as control group's mean plus two standard deviations. The Kruskal-Wallis test was used for analyzing differences between each B-epitopes response in P. vivax -exposed individuals' samples. * p
Figure Legend Snippet: IgG antibody response against four Pv RON2 B-cell epitopes ( n = 30). Seropositive samples were those above the cut-off point (0.218, dotted line), calculated as control group's mean plus two standard deviations. The Kruskal-Wallis test was used for analyzing differences between each B-epitopes response in P. vivax -exposed individuals' samples. * p

Techniques Used:

9) Product Images from "The in Vitro Antigenicity of Plasmodium vivax Rhoptry Neck Protein 2 (PvRON2) B- and T-Epitopes Selected by HLA-DRB1 Binding Profile"

Article Title: The in Vitro Antigenicity of Plasmodium vivax Rhoptry Neck Protein 2 (PvRON2) B- and T-Epitopes Selected by HLA-DRB1 Binding Profile

Journal: Frontiers in Cellular and Infection Microbiology

doi: 10.3389/fcimb.2018.00156

Evaluating IgG subclass response to the 39041 epitope ( n = 6). The Kruskal-Wallis test was used for analyzing differences between each IgG subclass response in P. vivax -exposed individuals' samples. ** p
Figure Legend Snippet: Evaluating IgG subclass response to the 39041 epitope ( n = 6). The Kruskal-Wallis test was used for analyzing differences between each IgG subclass response in P. vivax -exposed individuals' samples. ** p

Techniques Used:

IgG antibody response to Pv RON2 B epitopes by endemic area. Significant differences (calculated by Mann-Whitney test) between samples from Colombia's Chocó ( n = 13) and Córdoba ( n = 17) departments are shown. The dashed line indicates the cut-off point for seropositive samples. * p
Figure Legend Snippet: IgG antibody response to Pv RON2 B epitopes by endemic area. Significant differences (calculated by Mann-Whitney test) between samples from Colombia's Chocó ( n = 13) and Córdoba ( n = 17) departments are shown. The dashed line indicates the cut-off point for seropositive samples. * p

Techniques Used: MANN-WHITNEY

IgG antibody response against four Pv RON2 B-cell epitopes ( n = 30). Seropositive samples were those above the cut-off point (0.218, dotted line), calculated as control group's mean plus two standard deviations. The Kruskal-Wallis test was used for analyzing differences between each B-epitopes response in P. vivax -exposed individuals' samples. * p
Figure Legend Snippet: IgG antibody response against four Pv RON2 B-cell epitopes ( n = 30). Seropositive samples were those above the cut-off point (0.218, dotted line), calculated as control group's mean plus two standard deviations. The Kruskal-Wallis test was used for analyzing differences between each B-epitopes response in P. vivax -exposed individuals' samples. * p

Techniques Used:

10) Product Images from "IgG subclass response to Helicobacter pylori and CagA antigens in children"

Article Title: IgG subclass response to Helicobacter pylori and CagA antigens in children

Journal: Clinical and Experimental Immunology

doi: 10.1111/j.1365-2249.2003.02304.x

CagA IgG Units in H. pylori infected children with active ( n = 67) versus inactive ( n = 8) gastritis (Mann–Whitney U -test, P
Figure Legend Snippet: CagA IgG Units in H. pylori infected children with active ( n = 67) versus inactive ( n = 8) gastritis (Mann–Whitney U -test, P

Techniques Used: Infection, MANN-WHITNEY

11) Product Images from "Inducible dopaminergic glutathione depletion in an alpha-synuclein transgenic mouse model results in age-related olfactory dysfunction"

Article Title: Inducible dopaminergic glutathione depletion in an alpha-synuclein transgenic mouse model results in age-related olfactory dysfunction

Journal: Neuroscience

doi: 10.1016/j.neuroscience.2010.10.072

Immunohistochemistry of alpha-synuclein (A, C, E, G, and I) and TH (B, D, F, H, and J) labeled OB cells. Boxes in A and B were shown enlarged in C and D, respectively. Top row and bottom row are neighboring sections at the same scale. Red arrows in C,
Figure Legend Snippet: Immunohistochemistry of alpha-synuclein (A, C, E, G, and I) and TH (B, D, F, H, and J) labeled OB cells. Boxes in A and B were shown enlarged in C and D, respectively. Top row and bottom row are neighboring sections at the same scale. Red arrows in C,

Techniques Used: Immunohistochemistry, Labeling

12) Product Images from "Biochemical Characterization and Evaluation of a Brugia malayi Small Heat Shock Protein as a Vaccine against Lymphatic Filariasis"

Article Title: Biochemical Characterization and Evaluation of a Brugia malayi Small Heat Shock Protein as a Vaccine against Lymphatic Filariasis

Journal: PLoS ONE

doi: 10.1371/journal.pone.0034077

Isotype of anti-BmHsp12.6 IgG antibodies in the sera of mice. Mice were immunized with A ) BmHsp12.6, B ) BmHsp12.6αc or C ) N-BmHsp12.6 using homologous DNA vaccine regimen or a heterologous prime boost approach. Control mice were immunized with vector alone or adjuvant. Isotype specific ELISA was performed as described in the methods section. Bars represent mean O.D ± SD from five mice per group. * Significant (p
Figure Legend Snippet: Isotype of anti-BmHsp12.6 IgG antibodies in the sera of mice. Mice were immunized with A ) BmHsp12.6, B ) BmHsp12.6αc or C ) N-BmHsp12.6 using homologous DNA vaccine regimen or a heterologous prime boost approach. Control mice were immunized with vector alone or adjuvant. Isotype specific ELISA was performed as described in the methods section. Bars represent mean O.D ± SD from five mice per group. * Significant (p

Techniques Used: Mouse Assay, Plasmid Preparation, Enzyme-linked Immunosorbent Assay

Titer of IgG antibodies. Mice were immunized with A ) BmHsp12.6, B ) BmHsp12.6αc or C ) N-BmHsp12.6 using homologous DNA vaccine regimen or a heterologous prime boost approach. Approximately, 100 ng of peptides or proteins respectively (100 ng/100 µl/well) were coated on to the wells of an ELISA plate and bound serum IgG was detected using an HRP-labeled anti-mouse IgG secondary antibody. Each data point indicates mean (± S.D) value from five animals.
Figure Legend Snippet: Titer of IgG antibodies. Mice were immunized with A ) BmHsp12.6, B ) BmHsp12.6αc or C ) N-BmHsp12.6 using homologous DNA vaccine regimen or a heterologous prime boost approach. Approximately, 100 ng of peptides or proteins respectively (100 ng/100 µl/well) were coated on to the wells of an ELISA plate and bound serum IgG was detected using an HRP-labeled anti-mouse IgG secondary antibody. Each data point indicates mean (± S.D) value from five animals.

Techniques Used: Mouse Assay, Enzyme-linked Immunosorbent Assay, Labeling

Anti-rBmHsp12.6 IgG antibody isotypes in the human sera. IgG isotype antibodies against ( A ) rBmHsp12.6 protein, ( B ) BmHsp12.6αc peptide or ( C ) N-BmHsp12.6 in the sera of EN, MF, CP and NEN subjects were measured using an indirect ELISA. A total of 20 sera samples were evaluated from EN, MF, and CP from NEN. Each data point represents sera sample from a single individual. Each bar represents the mean ± SD of five patients from each group. * Significant (p
Figure Legend Snippet: Anti-rBmHsp12.6 IgG antibody isotypes in the human sera. IgG isotype antibodies against ( A ) rBmHsp12.6 protein, ( B ) BmHsp12.6αc peptide or ( C ) N-BmHsp12.6 in the sera of EN, MF, CP and NEN subjects were measured using an indirect ELISA. A total of 20 sera samples were evaluated from EN, MF, and CP from NEN. Each data point represents sera sample from a single individual. Each bar represents the mean ± SD of five patients from each group. * Significant (p

Techniques Used: Indirect ELISA

Anti-rBmHsp12.6 IgG antibody levels in the sera of human. Levels of total IgG antibodies against ( A ) rBmHsp12.6 protein, ( B ) BmHsp12.6αc peptide or ( C ) N-BmHsp12.6 peptide in the sera of EN, MF, CP and NEN subjects were measured using an indirect ELISA. A total of 20 sera samples were evaluated from EN, MF, and CP and 10 samples from NEN. Each data point represents sera sample from a single individual. Horizontal lines represent geometric mean value. Data is represented as scatter plot where each dot represents absorbance of individual sera.
Figure Legend Snippet: Anti-rBmHsp12.6 IgG antibody levels in the sera of human. Levels of total IgG antibodies against ( A ) rBmHsp12.6 protein, ( B ) BmHsp12.6αc peptide or ( C ) N-BmHsp12.6 peptide in the sera of EN, MF, CP and NEN subjects were measured using an indirect ELISA. A total of 20 sera samples were evaluated from EN, MF, and CP and 10 samples from NEN. Each data point represents sera sample from a single individual. Horizontal lines represent geometric mean value. Data is represented as scatter plot where each dot represents absorbance of individual sera.

Techniques Used: Indirect ELISA

13) Product Images from "Immune response studies with Wuchereria bancrofti vespid allergen homologue (WbVAH) in human lymphatic filariasis"

Article Title: Immune response studies with Wuchereria bancrofti vespid allergen homologue (WbVAH) in human lymphatic filariasis

Journal: Parasitology research

doi: 10.1007/s00436-007-0571-2

Levels of WbVAH-specific IgG antibodies in the sera of various clinical groups of lymphatic filariasis. Wells were coated with rWbVAH and sera collected from EN, MF, and CP patients were added at 1:100 dilution. a Levels of total IgG reactivity were determined by ELISA. Sera from 10 subjects were tested in each group. Each dot in the scatter plot indicates individual sera. Total IgG reactivity with WbVAH was significantly higher in EN ( P
Figure Legend Snippet: Levels of WbVAH-specific IgG antibodies in the sera of various clinical groups of lymphatic filariasis. Wells were coated with rWbVAH and sera collected from EN, MF, and CP patients were added at 1:100 dilution. a Levels of total IgG reactivity were determined by ELISA. Sera from 10 subjects were tested in each group. Each dot in the scatter plot indicates individual sera. Total IgG reactivity with WbVAH was significantly higher in EN ( P

Techniques Used: Enzyme-linked Immunosorbent Assay

14) Product Images from "Evaluation of Wuchereria bancrofti GST as a Vaccine Candidate for Lymphatic Filariasis"

Article Title: Evaluation of Wuchereria bancrofti GST as a Vaccine Candidate for Lymphatic Filariasis

Journal: PLoS Neglected Tropical Diseases

doi: 10.1371/journal.pntd.0000457

Subclass specific anti-WbGST IgG antibodies in the sera of mice immunized with rWbGST protein. Subclass analysis was performed using a mouse antibody isotyping ELISA kit. The bars represent the mean O.D.±SD at 405 nm of five mice per group.
Figure Legend Snippet: Subclass specific anti-WbGST IgG antibodies in the sera of mice immunized with rWbGST protein. Subclass analysis was performed using a mouse antibody isotyping ELISA kit. The bars represent the mean O.D.±SD at 405 nm of five mice per group.

Techniques Used: Mouse Assay, Enzyme-linked Immunosorbent Assay

Human immune responses to WbGST. A. Immunoreactivity of rWbGST with sera from different clinical groups of bancroftian filariasis. Approximately 1 µg of rWbGST was resolved on 15% SDS-PAGE, transferred to nitrocellulose membrane and blots were probed with pooled sera from MF, CP, EN or NEN individuals. Results showed strong immunoreactivity with pooled EN sera followed by CP and MF but no reactivity was detected with control NEN sera. Data is representative of one of three experiments using the same sera samples. B. Humoral immune response to rWbGST in human subjects. Total IgG levels against rWbGST in various clinical groups were evaluated by ELISA. Each data point represents single individual absorbance from the four different groups. Horizontal lines represent geometric mean value of EN (43), Mf (45), CP (45) and NEN (39) samples respectively. C. WbGST-specific IgG subclasses in the sera from different clinical groups. Isotype of anti-WbGST IgG antibodies in the sera from various groups of human subjects (EN, MF, CP, TPE and NEN) were evaluated using an isotype-specific ELISA. Data presented is mean±SD value from EN (43), Mf (45), CP (45) and NEN (39). * Significant (p
Figure Legend Snippet: Human immune responses to WbGST. A. Immunoreactivity of rWbGST with sera from different clinical groups of bancroftian filariasis. Approximately 1 µg of rWbGST was resolved on 15% SDS-PAGE, transferred to nitrocellulose membrane and blots were probed with pooled sera from MF, CP, EN or NEN individuals. Results showed strong immunoreactivity with pooled EN sera followed by CP and MF but no reactivity was detected with control NEN sera. Data is representative of one of three experiments using the same sera samples. B. Humoral immune response to rWbGST in human subjects. Total IgG levels against rWbGST in various clinical groups were evaluated by ELISA. Each data point represents single individual absorbance from the four different groups. Horizontal lines represent geometric mean value of EN (43), Mf (45), CP (45) and NEN (39) samples respectively. C. WbGST-specific IgG subclasses in the sera from different clinical groups. Isotype of anti-WbGST IgG antibodies in the sera from various groups of human subjects (EN, MF, CP, TPE and NEN) were evaluated using an isotype-specific ELISA. Data presented is mean±SD value from EN (43), Mf (45), CP (45) and NEN (39). * Significant (p

Techniques Used: SDS Page, Enzyme-linked Immunosorbent Assay

15) Product Images from "The CD44v7/8 Epitope as a Target to Restrain Proliferation of Fibroblast-Like Synoviocytes in Rheumatoid Arthritis"

Article Title: The CD44v7/8 Epitope as a Target to Restrain Proliferation of Fibroblast-Like Synoviocytes in Rheumatoid Arthritis

Journal: The American Journal of Pathology

doi:

Expression of splice variant CD44v7/8 in synovial membrane of patients with RA. Synovial specimens were snap-frozen, sectioned, and were either stained with 1% (w/v) toluidine blue in acetate buffer for 5 minutes to control tissue integrity (histology), or incubated with matching control-mouse IgG (neg control) or antibodies against exons CD44v7/8 (CD44v7/8). A second anti-mouse IgG1 antibody, labeled with fluorescein isothiocyanate was used to visualize binding of primary antibody. This figure is representative of two controls (normal) and four arthritic (RA) specimen tested.
Figure Legend Snippet: Expression of splice variant CD44v7/8 in synovial membrane of patients with RA. Synovial specimens were snap-frozen, sectioned, and were either stained with 1% (w/v) toluidine blue in acetate buffer for 5 minutes to control tissue integrity (histology), or incubated with matching control-mouse IgG (neg control) or antibodies against exons CD44v7/8 (CD44v7/8). A second anti-mouse IgG1 antibody, labeled with fluorescein isothiocyanate was used to visualize binding of primary antibody. This figure is representative of two controls (normal) and four arthritic (RA) specimen tested.

Techniques Used: Expressing, Variant Assay, Staining, Incubation, Labeling, Binding Assay

A: RT-PCR analysis of CD44 mRNA expression in freshly dissected fibroblast-like synoviocytes from nondiseased (normal) and diseased (RA) joints. RNA was isolated and subjected to RT-PCR using CD44 and glyceraldehyde-3-phosphate-specific primers in the presence of [α- 33 P]dATP. PCR products were separated on an acrylamide gel and radioactivity was visualized using a phosphorimager. Note the appearance of high molecular weight CD44 splice variants (500 to 1,000 bp), at 30 rounds of amplification, in RA-derived tissue but not in normal tissue. This figure represents three controls (Normal) and four arthritic (RA) specimens tested. B: Southern blotting with exon-specific probes reveals the presence of variant exon v7 and v8 in patients with RA. Nonlabeled RT-PCR products were blotted onto nylon membrane and probed with 32 P-labeled v7- and v8-specific oligonucleotides. Radioactivity was visualized using a phosphorimager. Note the absence of v7 and v8 in nondiseased joints (normal) and their presence in patients with RA. There is only one splicing combination (∼1.2 kb) that contains both v7 and v8. This autoradiograph is representative of three controls (normal) and four arthritic (RA) specimens tested. C: Immunoblotting reveals the presence of a single CD44 isoform (Mr 100 kd) containing the v7/8 epitope. Cells obtained from two patients with RA were lysed and subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Protein was transferred onto a polyvinylidene difluoride membrane and probed with antibodies that recognize the core protein of CD44 (CD44) or those that recognize variable exons v7/8 (CD44v7/8). Antibody binding was visualized after addition of a second, peroxidase-conjugated anti-mouse IgG antibody in an enhanced chemiluminescence protocol. Note the presence of numerous isoforms of CD44 in patients with RA but only a single protein band that contains both exons v7 and v8.
Figure Legend Snippet: A: RT-PCR analysis of CD44 mRNA expression in freshly dissected fibroblast-like synoviocytes from nondiseased (normal) and diseased (RA) joints. RNA was isolated and subjected to RT-PCR using CD44 and glyceraldehyde-3-phosphate-specific primers in the presence of [α- 33 P]dATP. PCR products were separated on an acrylamide gel and radioactivity was visualized using a phosphorimager. Note the appearance of high molecular weight CD44 splice variants (500 to 1,000 bp), at 30 rounds of amplification, in RA-derived tissue but not in normal tissue. This figure represents three controls (Normal) and four arthritic (RA) specimens tested. B: Southern blotting with exon-specific probes reveals the presence of variant exon v7 and v8 in patients with RA. Nonlabeled RT-PCR products were blotted onto nylon membrane and probed with 32 P-labeled v7- and v8-specific oligonucleotides. Radioactivity was visualized using a phosphorimager. Note the absence of v7 and v8 in nondiseased joints (normal) and their presence in patients with RA. There is only one splicing combination (∼1.2 kb) that contains both v7 and v8. This autoradiograph is representative of three controls (normal) and four arthritic (RA) specimens tested. C: Immunoblotting reveals the presence of a single CD44 isoform (Mr 100 kd) containing the v7/8 epitope. Cells obtained from two patients with RA were lysed and subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Protein was transferred onto a polyvinylidene difluoride membrane and probed with antibodies that recognize the core protein of CD44 (CD44) or those that recognize variable exons v7/8 (CD44v7/8). Antibody binding was visualized after addition of a second, peroxidase-conjugated anti-mouse IgG antibody in an enhanced chemiluminescence protocol. Note the presence of numerous isoforms of CD44 in patients with RA but only a single protein band that contains both exons v7 and v8.

Techniques Used: Reverse Transcription Polymerase Chain Reaction, Expressing, Isolation, Polymerase Chain Reaction, Acrylamide Gel Assay, Radioactivity, Molecular Weight, Amplification, Derivative Assay, Southern Blot, Variant Assay, Labeling, Autoradiography, Polyacrylamide Gel Electrophoresis, Binding Assay

16) Product Images from "Immunotherapy With the PreS-based Grass Pollen Allergy Vaccine BM32 Induces Antibody Responses Protecting Against Hepatitis B Infection"

Article Title: Immunotherapy With the PreS-based Grass Pollen Allergy Vaccine BM32 Induces Antibody Responses Protecting Against Hepatitis B Infection

Journal: EBioMedicine

doi: 10.1016/j.ebiom.2016.07.023

IgG responses of subjects vaccinated with BM32 or placebo and of hepatitis B virus-infected individuals specific for preS peptides. Shown are optical density values (y-axes: OD values) of IgG levels specific for preS-derived peptides (P1–P8) of subjects immunized with placebo (n = 8), 20 μg (n = 10) or 40 μg of BM32 (n = 12) at visit 15 as well as of HBV-infected individuals (n = 19) (x-axes). Medians are indicated by horizontal lines. P1 (aa 2–31); P2 (aa 22–51); P3 (aa 42–71); P4 (aa 62–91); P5 (aa 82–111); P6 (aa 102–131); P7 (aa 122–151); P8 (aa 142–174).
Figure Legend Snippet: IgG responses of subjects vaccinated with BM32 or placebo and of hepatitis B virus-infected individuals specific for preS peptides. Shown are optical density values (y-axes: OD values) of IgG levels specific for preS-derived peptides (P1–P8) of subjects immunized with placebo (n = 8), 20 μg (n = 10) or 40 μg of BM32 (n = 12) at visit 15 as well as of HBV-infected individuals (n = 19) (x-axes). Medians are indicated by horizontal lines. P1 (aa 2–31); P2 (aa 22–51); P3 (aa 42–71); P4 (aa 62–91); P5 (aa 82–111); P6 (aa 102–131); P7 (aa 122–151); P8 (aa 142–174).

Techniques Used: Infection, Derivative Assay

Overview of the treatment period of the BM32 trial. (a) Subjects received seven injections of placebo or BM32 over two years as depicted in the time line. Visits during which blood samples were obtained are indicated. (b) IgG responses of subjects vaccinated with BM32 or placebo towards preS and synthetic preS-derived overlapping peptides. Shown are optical density values (y-axes: OD values, means of triplicate determination) corresponding to IgG levels towards preS and peptides P1–P8 measured in subjects with (red symbols) or without (black symbols) prior HBV vaccination who had been immunized with BM32 or placebo before (V5) and at different time points after immunization (V8 and V15) (x-axes). Medians (horizontal bars) and significant differences are indicated: * P
Figure Legend Snippet: Overview of the treatment period of the BM32 trial. (a) Subjects received seven injections of placebo or BM32 over two years as depicted in the time line. Visits during which blood samples were obtained are indicated. (b) IgG responses of subjects vaccinated with BM32 or placebo towards preS and synthetic preS-derived overlapping peptides. Shown are optical density values (y-axes: OD values, means of triplicate determination) corresponding to IgG levels towards preS and peptides P1–P8 measured in subjects with (red symbols) or without (black symbols) prior HBV vaccination who had been immunized with BM32 or placebo before (V5) and at different time points after immunization (V8 and V15) (x-axes). Medians (horizontal bars) and significant differences are indicated: * P

Techniques Used: Derivative Assay

IgG responses towards preS and synthetic preS-derived overlapping peptides. Optical density values (y-axes: OD values at 405 nm) corresponding to IgG levels of rabbits immunized with (a) preS (n = 1), (b) 20 μg of BM32 (n = 2), (c) 40 μg of BM32 (n = 2) or to IgG 1 levels of groups of mice (n = 6) immunized with (d) 10 μg, (e) 20 μg or (f) 30 μg of BM32 prior to (grey bars) and after (black bars) immunization, towards preS and synthetic preS overlapping peptides P1–P8 (x-axes). Results represent medians ± interquartile ranges from triplicate determinations.
Figure Legend Snippet: IgG responses towards preS and synthetic preS-derived overlapping peptides. Optical density values (y-axes: OD values at 405 nm) corresponding to IgG levels of rabbits immunized with (a) preS (n = 1), (b) 20 μg of BM32 (n = 2), (c) 40 μg of BM32 (n = 2) or to IgG 1 levels of groups of mice (n = 6) immunized with (d) 10 μg, (e) 20 μg or (f) 30 μg of BM32 prior to (grey bars) and after (black bars) immunization, towards preS and synthetic preS overlapping peptides P1–P8 (x-axes). Results represent medians ± interquartile ranges from triplicate determinations.

Techniques Used: Derivative Assay, Mouse Assay

PreS-specific antibody responses of subjects vaccinated with BM32 or placebo and of HBV-infected individuals. Shown are optical density values (y-axes: OD values) of IgA, IgE, IgM, IgG and IgG subclass (IgG 1 –IgG 4 ) levels specific for preS of subjects immunized with placebo (n = 8), 20 μg (n = 10) or 40 μg of BM32 (n = 12) at visit 15 as well as of HBV-infected individuals (n = 19) (x-axes). Medians are indicated by horizontal lines, significant differences are indicated: *** P
Figure Legend Snippet: PreS-specific antibody responses of subjects vaccinated with BM32 or placebo and of HBV-infected individuals. Shown are optical density values (y-axes: OD values) of IgA, IgE, IgM, IgG and IgG subclass (IgG 1 –IgG 4 ) levels specific for preS of subjects immunized with placebo (n = 8), 20 μg (n = 10) or 40 μg of BM32 (n = 12) at visit 15 as well as of HBV-infected individuals (n = 19) (x-axes). Medians are indicated by horizontal lines, significant differences are indicated: *** P

Techniques Used: Infection

17) Product Images from "Transcutaneous Immunization with Cross-Reacting Material CRM197 of Diphtheria Toxin Boosts Functional Antibody Levels in Mice Primed Parenterally with Adsorbed Diphtheria Toxoid Vaccine "

Article Title: Transcutaneous Immunization with Cross-Reacting Material CRM197 of Diphtheria Toxin Boosts Functional Antibody Levels in Mice Primed Parenterally with Adsorbed Diphtheria Toxoid Vaccine

Journal: Infection and Immunity

doi: 10.1128/IAI.00797-07

IgG1 and IgG2a subclasses of antibodies elicited after transcutaneous boost with CRM 197 given with or without adjuvant or subcutaneous boost with adsorbed DTxd vaccine. Data are presented as individual anti-CRM 197 or anti-DTxd IgG1 (A) and anti-CRM 197
Figure Legend Snippet: IgG1 and IgG2a subclasses of antibodies elicited after transcutaneous boost with CRM 197 given with or without adjuvant or subcutaneous boost with adsorbed DTxd vaccine. Data are presented as individual anti-CRM 197 or anti-DTxd IgG1 (A) and anti-CRM 197

Techniques Used:

18) Product Images from "Expression, Purification, and Characterization of the Immunological Response to a 40-Kilodalton Plasmodium vivax Tryptophan-Rich Antigen "

Article Title: Expression, Purification, and Characterization of the Immunological Response to a 40-Kilodalton Plasmodium vivax Tryptophan-Rich Antigen

Journal: Infection and Immunity

doi: 10.1128/IAI.00677-07

Levels of IgG1 and IgG4 antibodies against PvTRAg40 in a group of recovered patients. ELISA was performed on serum samples ( n = 24) from individuals who had been exposed to P. vivax infection 8 to 14 weeks prior to sample collection, using HPLC-purified PvTRAg40 and biotin-labeled monoclonal anti-human IgG1 or IgG4. The levels of IgG4 antibodies were significantly higher than those of IgG1 ( P
Figure Legend Snippet: Levels of IgG1 and IgG4 antibodies against PvTRAg40 in a group of recovered patients. ELISA was performed on serum samples ( n = 24) from individuals who had been exposed to P. vivax infection 8 to 14 weeks prior to sample collection, using HPLC-purified PvTRAg40 and biotin-labeled monoclonal anti-human IgG1 or IgG4. The levels of IgG4 antibodies were significantly higher than those of IgG1 ( P

Techniques Used: Enzyme-linked Immunosorbent Assay, Infection, High Performance Liquid Chromatography, Purification, Labeling

19) Product Images from "In Vitro Formation of Recycling Vesicles from Endosomes Requires Adaptor Protein-1/Clathrin and Is Regulated by Rab4 and the Connector Rabaptin-5"

Article Title: In Vitro Formation of Recycling Vesicles from Endosomes Requires Adaptor Protein-1/Clathrin and Is Regulated by Rab4 and the Connector Rabaptin-5

Journal: Molecular Biology of the Cell

doi: 10.1091/mbc.E04-04-0355

Electron microscopic visualization of H1-containing endosomal vesicles. (A) H1 at the cell surface was decorated with nanogold-coupled anti-H1 F(ab′) fragments and allowed to internalize for 10 min. Cells were stripped of surface antibody; permeabilized; incubated with cytosol, nucleotides, and ATP-regenerating system; and sedimented. Membranes in the supernatant were collected by high-speed centrifugation and subjected to cryoelectron microscopy and silver enhancement of nanogold. (B and C) As in A, but in addition decorated with anti-γ-adaptin and a secondary anti-mouse IgG antibody coupled to 10-nm colloidal gold. Arrowheads indicate colloidal gold particles, which have a more dense appearance than silver-enhanced nanogold particles. Bar, 200 nm.
Figure Legend Snippet: Electron microscopic visualization of H1-containing endosomal vesicles. (A) H1 at the cell surface was decorated with nanogold-coupled anti-H1 F(ab′) fragments and allowed to internalize for 10 min. Cells were stripped of surface antibody; permeabilized; incubated with cytosol, nucleotides, and ATP-regenerating system; and sedimented. Membranes in the supernatant were collected by high-speed centrifugation and subjected to cryoelectron microscopy and silver enhancement of nanogold. (B and C) As in A, but in addition decorated with anti-γ-adaptin and a secondary anti-mouse IgG antibody coupled to 10-nm colloidal gold. Arrowheads indicate colloidal gold particles, which have a more dense appearance than silver-enhanced nanogold particles. Bar, 200 nm.

Techniques Used: Incubation, Centrifugation, Microscopy

20) Product Images from "Monoclonal IgG antibodies generated from joint-derived B cells of RA patients have a strong bias toward citrullinated autoantigen recognition"

Article Title: Monoclonal IgG antibodies generated from joint-derived B cells of RA patients have a strong bias toward citrullinated autoantigen recognition

Journal: The Journal of Experimental Medicine

doi: 10.1084/jem.20121486

Citrulline-reactive antibodies display a bias toward nonsynonymous mutations in the CDRs. (a) Comparison of the absolute numbers of somatic mutations in individual VH, Vκ, and Vλ genes of the antibodies generated from ACPA + and ACPA − patients. (b) Frequencies of replacement (R) and silent (S) mutations in the CDRs and FWRs of VH, Vκ, and Vλ genes of synovial IgG + memory B cells from ACPA + and ACPA − RA patients. (c) Comparison of the absolute numbers of somatic mutations between citrulline-positive versus -negative antibodies generated from ACPA + patients. (d) R/S mutation ratios in the CDRs and FWRs of the VH, Vκ, and Vλ genes in the citrulline-positive and -negative clones generated from ACPA + patients. (e) Absolute numbers of somatic mutations in individual VH and IgL genes of the antibodies generated from the individual patient samples. (a, c, and e) Horizontal bars indicate mean. (f and g) Frequencies of R and S mutations in the CDRs and FWRs of VH and VL of synovial IgG + memory B cell from the individual ACPA + (f) and ACPA − (g) RA patients. The R/S ratios are indicated below the respective graphs.
Figure Legend Snippet: Citrulline-reactive antibodies display a bias toward nonsynonymous mutations in the CDRs. (a) Comparison of the absolute numbers of somatic mutations in individual VH, Vκ, and Vλ genes of the antibodies generated from ACPA + and ACPA − patients. (b) Frequencies of replacement (R) and silent (S) mutations in the CDRs and FWRs of VH, Vκ, and Vλ genes of synovial IgG + memory B cells from ACPA + and ACPA − RA patients. (c) Comparison of the absolute numbers of somatic mutations between citrulline-positive versus -negative antibodies generated from ACPA + patients. (d) R/S mutation ratios in the CDRs and FWRs of the VH, Vκ, and Vλ genes in the citrulline-positive and -negative clones generated from ACPA + patients. (e) Absolute numbers of somatic mutations in individual VH and IgL genes of the antibodies generated from the individual patient samples. (a, c, and e) Horizontal bars indicate mean. (f and g) Frequencies of R and S mutations in the CDRs and FWRs of VH and VL of synovial IgG + memory B cell from the individual ACPA + (f) and ACPA − (g) RA patients. The R/S ratios are indicated below the respective graphs.

Techniques Used: Generated, Mutagenesis, Clone Assay

Immunohistochemical localization of citrullinated proteins in synovial tissues of RA patients. (a and b) Immunohistochemistry using two of the recombinant citrulline-specific antibodies, 1276SF-D10 (a) and 1325SF-B109 (b), brown staining of both the lining (black arrows) and sublining (white arrows) layers in an inflamed synovial biopsy, obtained at the time of joint arthroplasty from a RA patient. (c) Staining of a matched irrelevant IgG2a-negative control used at similar concentration. Insets show the same samples at higher magnification. Similar results were observed in two other RA synovial tissues (not depicted). Data presented in this figure are representative of three independent experiments from four patients. Bars, 68 µm.
Figure Legend Snippet: Immunohistochemical localization of citrullinated proteins in synovial tissues of RA patients. (a and b) Immunohistochemistry using two of the recombinant citrulline-specific antibodies, 1276SF-D10 (a) and 1325SF-B109 (b), brown staining of both the lining (black arrows) and sublining (white arrows) layers in an inflamed synovial biopsy, obtained at the time of joint arthroplasty from a RA patient. (c) Staining of a matched irrelevant IgG2a-negative control used at similar concentration. Insets show the same samples at higher magnification. Similar results were observed in two other RA synovial tissues (not depicted). Data presented in this figure are representative of three independent experiments from four patients. Bars, 68 µm.

Techniques Used: Immunohistochemistry, Recombinant, Staining, Negative Control, Concentration Assay

Similar IgG gene characteristic in synovial B cells from ACPA + and ACPA − RA patients. (a) Summary of VH and JH family gene usage in seropositive (ACPA + ) and negative (ACPA − ) patient samples. (b) Overview of IgH (γ) CDR3 amino acid characteristics: length (left) and negatively (middle) and positively (right) charged amino acids in ACPA + and ACPA − patients. (c and d) Light chains data depicting Vκ/Jκ (c) and Vλ/Jλ (d) gene family usage. (e) Distribution of IgG subclasses displayed per patient with the total number of sequences analyzed represented in the middle of the pie charts. (f) IgG subclass distribution in ACPA + and ACPA − patient samples. Differences between individual fractions were not statistically significant (P > 0.5), as determined by Fisher’s exact test.
Figure Legend Snippet: Similar IgG gene characteristic in synovial B cells from ACPA + and ACPA − RA patients. (a) Summary of VH and JH family gene usage in seropositive (ACPA + ) and negative (ACPA − ) patient samples. (b) Overview of IgH (γ) CDR3 amino acid characteristics: length (left) and negatively (middle) and positively (right) charged amino acids in ACPA + and ACPA − patients. (c and d) Light chains data depicting Vκ/Jκ (c) and Vλ/Jλ (d) gene family usage. (e) Distribution of IgG subclasses displayed per patient with the total number of sequences analyzed represented in the middle of the pie charts. (f) IgG subclass distribution in ACPA + and ACPA − patient samples. Differences between individual fractions were not statistically significant (P > 0.5), as determined by Fisher’s exact test.

Techniques Used:

Citrulline-reactive antibodies could be generated from ACPA + but not from ACPA − RA patients. (a) Pie charts summarizing the frequency of the citrulline-reactive clones (to any of the tested citrulline peptides) in individual patient samples. The top panel represents the three ACPA + patient samples and the three in the bottom panel, the ACPA − samples. The absolute number of tested antibodies is indicated in the center of each pie chart. (b) Frequency comparison of antigen reactivity in the clones generated from the different ACPA + and ACPA − patients (one symbol summarizes all generated antibodies from each individual; range 15–37 clones per patient sample; in total 93 antibodies were tested from ACPA + and 67 from ACPA − patients). CCP denotes general citrulline reactivity; polyreactivity is based on positivity of two or more of the following: insulin, LPS, and double-stranded DNA; and lastly tetanus toxoid was used as a proxy for recall response. Horizontal lines represent the mean values of reactivity for all RA patients. (c) ELISA graphs of the various ACPA fine specificities: CEP-1 (citrullinated α-enolase, amino acids 5–21), cit-fib (citrullinated fibrinogen, amino acids 36–52), and cit-vim (citrullinated vimentin, amino acids 60–75). Black lines represent individual IgG + memory B cells antibodies. (c) Green lines represent the high positive control (serum pool of ACPA + antibodies). (c and e) Red lines represent the negative control antibody (serum pool of ACPA − antibodies). Each vertical row represents one ACPA + patient sample. (d) ELISA graphs of the corresponding arginine versions of the peptides. (c–e) Dashed horizontal lines show a cutoff of OD450 for positive reactivity. (e) Sequences from four selected antibodies with high reactivity to two or more of the citrullinated peptides that were subsequently reverted into their predicted germline sequence (in both the FWRs and CDRs) and then expressed as recombinant antibodies. ELISA graphs illustrate the citrulline reactivity of the original antibodies (i.e., mutated; left) compared with those encoded by the predicted germline sequences (right). Data are representative of three to six independent experiments.
Figure Legend Snippet: Citrulline-reactive antibodies could be generated from ACPA + but not from ACPA − RA patients. (a) Pie charts summarizing the frequency of the citrulline-reactive clones (to any of the tested citrulline peptides) in individual patient samples. The top panel represents the three ACPA + patient samples and the three in the bottom panel, the ACPA − samples. The absolute number of tested antibodies is indicated in the center of each pie chart. (b) Frequency comparison of antigen reactivity in the clones generated from the different ACPA + and ACPA − patients (one symbol summarizes all generated antibodies from each individual; range 15–37 clones per patient sample; in total 93 antibodies were tested from ACPA + and 67 from ACPA − patients). CCP denotes general citrulline reactivity; polyreactivity is based on positivity of two or more of the following: insulin, LPS, and double-stranded DNA; and lastly tetanus toxoid was used as a proxy for recall response. Horizontal lines represent the mean values of reactivity for all RA patients. (c) ELISA graphs of the various ACPA fine specificities: CEP-1 (citrullinated α-enolase, amino acids 5–21), cit-fib (citrullinated fibrinogen, amino acids 36–52), and cit-vim (citrullinated vimentin, amino acids 60–75). Black lines represent individual IgG + memory B cells antibodies. (c) Green lines represent the high positive control (serum pool of ACPA + antibodies). (c and e) Red lines represent the negative control antibody (serum pool of ACPA − antibodies). Each vertical row represents one ACPA + patient sample. (d) ELISA graphs of the corresponding arginine versions of the peptides. (c–e) Dashed horizontal lines show a cutoff of OD450 for positive reactivity. (e) Sequences from four selected antibodies with high reactivity to two or more of the citrullinated peptides that were subsequently reverted into their predicted germline sequence (in both the FWRs and CDRs) and then expressed as recombinant antibodies. ELISA graphs illustrate the citrulline reactivity of the original antibodies (i.e., mutated; left) compared with those encoded by the predicted germline sequences (right). Data are representative of three to six independent experiments.

Techniques Used: Generated, Clone Assay, Enzyme-linked Immunosorbent Assay, Positive Control, Negative Control, Sequencing, Recombinant

21) Product Images from "Rat Macrophage C-Type Lectin Is an Activating Receptor Expressed by Phagocytic Cells"

Article Title: Rat Macrophage C-Type Lectin Is an Activating Receptor Expressed by Phagocytic Cells

Journal: PLoS ONE

doi: 10.1371/journal.pone.0057406

Immunostaining of rat spleen. Serial-cut frozen sections were stained with mAbs towards A, rat MCL B, rat CD169 C, rat MHC class II D, human MHC class I (negative control) and visualized with peroxidase-conjugated secondary antibody and DAB substrate. RP: red pulp. PALS: periarteriolar lymphoid sheath. FOLL: follicle. MZ: marginal zone.
Figure Legend Snippet: Immunostaining of rat spleen. Serial-cut frozen sections were stained with mAbs towards A, rat MCL B, rat CD169 C, rat MHC class II D, human MHC class I (negative control) and visualized with peroxidase-conjugated secondary antibody and DAB substrate. RP: red pulp. PALS: periarteriolar lymphoid sheath. FOLL: follicle. MZ: marginal zone.

Techniques Used: Immunostaining, Staining, Negative Control

22) Product Images from "Immune response studies with Wuchereria bancrofti vespid allergen homologue (WbVAH) in human lymphatic filariasis"

Article Title: Immune response studies with Wuchereria bancrofti vespid allergen homologue (WbVAH) in human lymphatic filariasis

Journal: Parasitology research

doi: 10.1007/s00436-007-0571-2

Levels of WbVAH-specific IgG antibodies in the sera of various clinical groups of lymphatic filariasis. Wells were coated with rWbVAH and sera collected from EN, MF, and CP patients were added at 1:100 dilution. a Levels of total IgG reactivity were determined by ELISA. Sera from 10 subjects were tested in each group. Each dot in the scatter plot indicates individual sera. Total IgG reactivity with WbVAH was significantly higher in EN ( P
Figure Legend Snippet: Levels of WbVAH-specific IgG antibodies in the sera of various clinical groups of lymphatic filariasis. Wells were coated with rWbVAH and sera collected from EN, MF, and CP patients were added at 1:100 dilution. a Levels of total IgG reactivity were determined by ELISA. Sera from 10 subjects were tested in each group. Each dot in the scatter plot indicates individual sera. Total IgG reactivity with WbVAH was significantly higher in EN ( P

Techniques Used: Enzyme-linked Immunosorbent Assay

23) Product Images from "CD36, a Class B Scavenger Receptor, Is Expressed on Microglia in Alzheimer's Disease Brains and Can Mediate Production of Reactive Oxygen Species in Response to ?-Amyloid Fibrils"

Article Title: CD36, a Class B Scavenger Receptor, Is Expressed on Microglia in Alzheimer's Disease Brains and Can Mediate Production of Reactive Oxygen Species in Response to ?-Amyloid Fibrils

Journal: The American Journal of Pathology

doi:

Bowes cells expressing CD36 gain the ability to bind to fAβ 1-42-coated surfaces. A: FACS analysis of Bowes melanoma cells transfected with a mammalian expression vector for human CD36 and stained with a monoclonal antibody FA6-152 to CD36. B: cells/ml), transfected with a mammalian expression vector for CD36 (CDM8-CD36) or with a control vector (PcDNAneo), and suspended in phosphate buffer containing 5 mmol/L EDTA, to multispot slides coated with 2 μg of collagen IV and the indicated amount of Aβ 1-42. C: Bowes melanoma cells expressing CD36 were incubated with the indicated concentrations of anti-CD36 monoclonal antibody FA6-152 or an isotype-matched IgG 1 control and plated on multispot slides coated with 2 μg of collagen IV and 500 ng of Aβ 1-42.
Figure Legend Snippet: Bowes cells expressing CD36 gain the ability to bind to fAβ 1-42-coated surfaces. A: FACS analysis of Bowes melanoma cells transfected with a mammalian expression vector for human CD36 and stained with a monoclonal antibody FA6-152 to CD36. B: cells/ml), transfected with a mammalian expression vector for CD36 (CDM8-CD36) or with a control vector (PcDNAneo), and suspended in phosphate buffer containing 5 mmol/L EDTA, to multispot slides coated with 2 μg of collagen IV and the indicated amount of Aβ 1-42. C: Bowes melanoma cells expressing CD36 were incubated with the indicated concentrations of anti-CD36 monoclonal antibody FA6-152 or an isotype-matched IgG 1 control and plated on multispot slides coated with 2 μg of collagen IV and 500 ng of Aβ 1-42.

Techniques Used: Expressing, FACS, Transfection, Plasmid Preparation, Staining, Incubation

24) Product Images from "Cytokine Profiles for Peripheral Blood Lymphocytes from Patients with Active Pulmonary Tuberculosis and Healthy Household Contacts in Response to the 30-Kilodalton Antigen of Mycobacterium tuberculosis"

Article Title: Cytokine Profiles for Peripheral Blood Lymphocytes from Patients with Active Pulmonary Tuberculosis and Healthy Household Contacts in Response to the 30-Kilodalton Antigen of Mycobacterium tuberculosis

Journal: Infection and Immunity

doi:

Detection of IgG subclasses directed against the 30-kDa Ag. Sera from patients with active TB were analyzed by ELISA for specific IgG subclass reactivity to 30-kDa Ag. Results are presented as mean OD units ± SE.
Figure Legend Snippet: Detection of IgG subclasses directed against the 30-kDa Ag. Sera from patients with active TB were analyzed by ELISA for specific IgG subclass reactivity to 30-kDa Ag. Results are presented as mean OD units ± SE.

Techniques Used: Enzyme-linked Immunosorbent Assay

25) Product Images from "An anti-MUC1-antibody-interleukin-2 fusion protein that activates resting NK cells to lysis of MUC1-positive tumour cells"

Article Title: An anti-MUC1-antibody-interleukin-2 fusion protein that activates resting NK cells to lysis of MUC1-positive tumour cells

Journal: British Journal of Cancer

doi: 10.1038/sj.bjc.6601267

Antigen binding profile of the recombinant fusion proteins C595scFv-Fc and C595scFv-Fc-IL2. Microtitre plates were coated with a set of MUC1-related (glyco-) peptides (10 μ g ml −1 ) corresponding to mono- and oligorepeats and containing the RPAP motif (see Table 1 ), partially deglycosylated MUC1 antigen (100 μ g ml −1 ), and, as control, BSM (100 μ g ml −1 ), an anti-human IgG antibody (1 μ g ml −1 ) and an anti-mouse IgG antibody (1 μ g ml −1 ), respectively. The coated wells were incubated with cell culture supernatants containing the fusion proteins C595scFv-Fc ( A ) and C595scFv-Fc-IL2 ( B ), respectively, and as control with the mAb C595 ( C ) and a mouse IgG1 control antibody ( D ) (both 0.25 μ g ml −1 ). Bound fusion proteins and antibodies were detected by a biotin-labelled anti-human IgG mAb ( A and B ) or a biotin labelled anti-mouse IgG mAb ( C and D ). The assay was performed in triplicate; data are presented as the mean±s.e.m.
Figure Legend Snippet: Antigen binding profile of the recombinant fusion proteins C595scFv-Fc and C595scFv-Fc-IL2. Microtitre plates were coated with a set of MUC1-related (glyco-) peptides (10 μ g ml −1 ) corresponding to mono- and oligorepeats and containing the RPAP motif (see Table 1 ), partially deglycosylated MUC1 antigen (100 μ g ml −1 ), and, as control, BSM (100 μ g ml −1 ), an anti-human IgG antibody (1 μ g ml −1 ) and an anti-mouse IgG antibody (1 μ g ml −1 ), respectively. The coated wells were incubated with cell culture supernatants containing the fusion proteins C595scFv-Fc ( A ) and C595scFv-Fc-IL2 ( B ), respectively, and as control with the mAb C595 ( C ) and a mouse IgG1 control antibody ( D ) (both 0.25 μ g ml −1 ). Bound fusion proteins and antibodies were detected by a biotin-labelled anti-human IgG mAb ( A and B ) or a biotin labelled anti-mouse IgG mAb ( C and D ). The assay was performed in triplicate; data are presented as the mean±s.e.m.

Techniques Used: Binding Assay, Recombinant, Incubation, Cell Culture

Detection of the fusion proteins C595scFv-Fc and C595scFv-Fc-IL2 in the supernatants of transfected 293 T cells. Serial dilutions of culture supernatants from 293 T cells transfected with pRSV-C595scFv-Fc (▪), pRSV-C595scFv-Fc-IL2 (•) and, as control, from mock-transfected cells (*), respectively, were incubated in microtitre plates coated with an anti-human IgG antibody. Bound fusion proteins were detected by a biotin-labelled anti-human IgG ( A ) or anti-human IL2 ( B ) antibody.
Figure Legend Snippet: Detection of the fusion proteins C595scFv-Fc and C595scFv-Fc-IL2 in the supernatants of transfected 293 T cells. Serial dilutions of culture supernatants from 293 T cells transfected with pRSV-C595scFv-Fc (▪), pRSV-C595scFv-Fc-IL2 (•) and, as control, from mock-transfected cells (*), respectively, were incubated in microtitre plates coated with an anti-human IgG antibody. Bound fusion proteins were detected by a biotin-labelled anti-human IgG ( A ) or anti-human IL2 ( B ) antibody.

Techniques Used: Transfection, Incubation

The fusion proteins C595scFv-Fc and C595scFv-Fc-IL2 are expressed as homodimers. Cell culture supernatants from 293 T cells transfected with pRSV-C595scFv-Fc DNA (lane 1) or with pRSV-C595scFv-Fc-IL2 DNA (lane 2) as well as recombinant human IL2 (1000 U, lane 3) were electrophoretically separated under nonreducing conditions, blotted onto nitrocellulose membrane and probed with an anti-human IgG antibody ( A ) and an anti-human IL2 antibody ( B ). The calculated molecular weight of the monomeric form of the fusion protein C595scFv-Fc is 60 kDa, of the C595scFv-Fc-IL2 protein is 75 kDa.
Figure Legend Snippet: The fusion proteins C595scFv-Fc and C595scFv-Fc-IL2 are expressed as homodimers. Cell culture supernatants from 293 T cells transfected with pRSV-C595scFv-Fc DNA (lane 1) or with pRSV-C595scFv-Fc-IL2 DNA (lane 2) as well as recombinant human IL2 (1000 U, lane 3) were electrophoretically separated under nonreducing conditions, blotted onto nitrocellulose membrane and probed with an anti-human IgG antibody ( A ) and an anti-human IL2 antibody ( B ). The calculated molecular weight of the monomeric form of the fusion protein C595scFv-Fc is 60 kDa, of the C595scFv-Fc-IL2 protein is 75 kDa.

Techniques Used: Cell Culture, Transfection, Recombinant, Molecular Weight

Fusion proteins C595scFv-Fc and C595scFv-Fc-IL2 bind specifically to MUC1 positive tumour cells and TR5 peptide-coated beads. Cell culture supernatants from transfected 293 T cells containing the C595scFv-Fc and C595scFv-Fc-IL2 fusion protein (thick lines), respectively, and, as control, supernatant from 293 T cells transfected with an irrelevant DNA (thin lines), were incubated ( A ) with T-47D cells (MUC1+/CD25−), 293 T cells (MUC1−/CD25−), L540 cells (MUC1−/CD25+), TR5 peptide-coated beads or, as control, with human serum albumin-coated beads, and ( B ) with quiescent lymphocytes from the peripheral blood (PBL) or with PBL activated by preincubation with the anti-CD3 mAb OKT3 plus IL2. Bound fusion proteins were detected by an FITC-labelled anti-human IgG antibody. Expression of the IL2 receptor CD25 was monitored by incubation with a FITC-conjugated anti-CD25 mAb (anti-CD25).
Figure Legend Snippet: Fusion proteins C595scFv-Fc and C595scFv-Fc-IL2 bind specifically to MUC1 positive tumour cells and TR5 peptide-coated beads. Cell culture supernatants from transfected 293 T cells containing the C595scFv-Fc and C595scFv-Fc-IL2 fusion protein (thick lines), respectively, and, as control, supernatant from 293 T cells transfected with an irrelevant DNA (thin lines), were incubated ( A ) with T-47D cells (MUC1+/CD25−), 293 T cells (MUC1−/CD25−), L540 cells (MUC1−/CD25+), TR5 peptide-coated beads or, as control, with human serum albumin-coated beads, and ( B ) with quiescent lymphocytes from the peripheral blood (PBL) or with PBL activated by preincubation with the anti-CD3 mAb OKT3 plus IL2. Bound fusion proteins were detected by an FITC-labelled anti-human IgG antibody. Expression of the IL2 receptor CD25 was monitored by incubation with a FITC-conjugated anti-CD25 mAb (anti-CD25).

Techniques Used: Cell Culture, Transfection, Incubation, Expressing

Expression cassettes coding for the recombinant anti-MUC1 fusion proteins C595scFv-Fc and C595scFv-Fc-IL2. The expression cassettes were generated as described in Materials and Methods. Lk: leader sequence of the Ig κ chain; C595scFv: anti-MUC1 scFv; Fc: IgG1 CH2CH3. The expression cassettes are driven by the RSV LTR.
Figure Legend Snippet: Expression cassettes coding for the recombinant anti-MUC1 fusion proteins C595scFv-Fc and C595scFv-Fc-IL2. The expression cassettes were generated as described in Materials and Methods. Lk: leader sequence of the Ig κ chain; C595scFv: anti-MUC1 scFv; Fc: IgG1 CH2CH3. The expression cassettes are driven by the RSV LTR.

Techniques Used: Expressing, Recombinant, Generated, Sequencing

Binding-inhibition assay. Microtitre plates coated with the peptide antigen TR5 (2.5 μ g ml −1 ) were incubated with dilutions of C595scFv-Fc (•), C595scFv-Fc-IL2 (▪), and C595 mAb (▴), respectively, that result in half-maximal binding. The binding to immobilized TR5 antigen was specifically competed by addition of increasing amounts of soluble TR5 antigen. Bound fusion proteins were detected by the biotin-labelled anti-human IgG antibody; bound C595 mAb was detected by the biotinylated anti-mouse IgG antibody. The percentage of inhibition was determined as described in ‘Material and Methods’.
Figure Legend Snippet: Binding-inhibition assay. Microtitre plates coated with the peptide antigen TR5 (2.5 μ g ml −1 ) were incubated with dilutions of C595scFv-Fc (•), C595scFv-Fc-IL2 (▪), and C595 mAb (▴), respectively, that result in half-maximal binding. The binding to immobilized TR5 antigen was specifically competed by addition of increasing amounts of soluble TR5 antigen. Bound fusion proteins were detected by the biotin-labelled anti-human IgG antibody; bound C595 mAb was detected by the biotinylated anti-mouse IgG antibody. The percentage of inhibition was determined as described in ‘Material and Methods’.

Techniques Used: Binding Assay, Inhibition, Incubation

26) Product Images from "Antibody responses to the RTS,S/AS01E vaccine and Plasmodium falciparum antigens after a booster dose within the phase 3 trial in Mozambique"

Article Title: Antibody responses to the RTS,S/AS01E vaccine and Plasmodium falciparum antigens after a booster dose within the phase 3 trial in Mozambique

Journal: NPJ Vaccines

doi: 10.1038/s41541-020-0192-7

Immunogenicity stratified by clinical malaria after M21: total IgG, IgG1-4 subclasses and IgM for CSP C-term at month (M) 20, 21, and 32 for RTS,S/AS01 vaccinees with (R3R) and without (R3C) booster, and comparator (C3C). Stratified analysis by malaria after M21, subjects who presented with clinical malaria (M = blue) and subjects without malaria (NM = red). Subjects who presented with clinical malaria before M20 are represented with green and orange squares. Boxplots with medians, interquartile ranges (IQR), upper whisker as the smallest between maximum × value and Q3 + 1.5*IQR, lower whisker as the largest between minimum × value and Q1 – 1.5*IQR, and log 10 (geometric mean(MFI)) (diamond). Non-parametric tests were used to compare levels with or without clinical malaria (NM vs. M). p -values were adjusted for multiple comparisons, but none was significant. Only p -values
Figure Legend Snippet: Immunogenicity stratified by clinical malaria after M21: total IgG, IgG1-4 subclasses and IgM for CSP C-term at month (M) 20, 21, and 32 for RTS,S/AS01 vaccinees with (R3R) and without (R3C) booster, and comparator (C3C). Stratified analysis by malaria after M21, subjects who presented with clinical malaria (M = blue) and subjects without malaria (NM = red). Subjects who presented with clinical malaria before M20 are represented with green and orange squares. Boxplots with medians, interquartile ranges (IQR), upper whisker as the smallest between maximum × value and Q3 + 1.5*IQR, lower whisker as the largest between minimum × value and Q1 – 1.5*IQR, and log 10 (geometric mean(MFI)) (diamond). Non-parametric tests were used to compare levels with or without clinical malaria (NM vs. M). p -values were adjusted for multiple comparisons, but none was significant. Only p -values

Techniques Used: Whisker Assay

Immunogenicity stratified by clinical malaria after M21: total IgG, IgG1-4 subclasses and IgM for HBsAg at month (M) 20, 21, and 32 for RTS,S/AS01 vaccinees with (R3R) and without (R3C) booster, and comparator (C3C). Stratified analysis by malaria after M21, subjects who presented with clinical malaria (M = blue) and subjects without malaria (NM = red). Subjects who presented with clinical malaria before M20 are represented with green and orange squares. Boxplots with medians, interquartile ranges (IQR), upper whisker as the smallest between maximum × value and Q3 + 1.5*IQR, lower whisker as the largest between minimum × value and Q1 – 1.5*IQR, and log 10 (geometric mean(MFI)) (diamond). Non-parametric tests were used to compare levels with or without clinical malaria (NM vs. M). p -values were adjusted for multiple comparisons, but none was significant. Only p -values
Figure Legend Snippet: Immunogenicity stratified by clinical malaria after M21: total IgG, IgG1-4 subclasses and IgM for HBsAg at month (M) 20, 21, and 32 for RTS,S/AS01 vaccinees with (R3R) and without (R3C) booster, and comparator (C3C). Stratified analysis by malaria after M21, subjects who presented with clinical malaria (M = blue) and subjects without malaria (NM = red). Subjects who presented with clinical malaria before M20 are represented with green and orange squares. Boxplots with medians, interquartile ranges (IQR), upper whisker as the smallest between maximum × value and Q3 + 1.5*IQR, lower whisker as the largest between minimum × value and Q1 – 1.5*IQR, and log 10 (geometric mean(MFI)) (diamond). Non-parametric tests were used to compare levels with or without clinical malaria (NM vs. M). p -values were adjusted for multiple comparisons, but none was significant. Only p -values

Techniques Used: Whisker Assay

Immunogenicity for CSP FL stratified by previous clinical malaria: total IgG, IgG1-4 subclasses and IgM at month (M)20, 21, and 32 for RTS,S/AS01 vaccinees with (R3R) and without (R3C) booster, and comparator (C3C). Stratified analysis by malaria cases before M20, subjects who presented with clinical malaria (M = blue) and subjects without malaria (NM = red). Boxplots with medians, interquartile ranges (IQR), upper whisker as the smallest between maximum × value and Q3 + 1.5*IQR, lower whisker as the largest between minimum × value and Q1 – 1.5*IQR, and log 10 (geometric mean(MFI)) (diamond). Non-parametric tests were used to compare levels with or without clinical malaria (M vs. NM). p -values were adjusted for multiple comparisons, but none was significant. Only p -values
Figure Legend Snippet: Immunogenicity for CSP FL stratified by previous clinical malaria: total IgG, IgG1-4 subclasses and IgM at month (M)20, 21, and 32 for RTS,S/AS01 vaccinees with (R3R) and without (R3C) booster, and comparator (C3C). Stratified analysis by malaria cases before M20, subjects who presented with clinical malaria (M = blue) and subjects without malaria (NM = red). Boxplots with medians, interquartile ranges (IQR), upper whisker as the smallest between maximum × value and Q3 + 1.5*IQR, lower whisker as the largest between minimum × value and Q1 – 1.5*IQR, and log 10 (geometric mean(MFI)) (diamond). Non-parametric tests were used to compare levels with or without clinical malaria (M vs. NM). p -values were adjusted for multiple comparisons, but none was significant. Only p -values

Techniques Used: Whisker Assay

Immunogenicity stratified by clinical malaria after M21: total IgG, IgG1-4 subclasses and IgM for CSP NANP at month (M) 20, 21, and 32 for RTS,S/AS01 vaccinees with (R3R) and without (R3C) booster, and comparator (C3C). Stratified analysis by malaria after M21, subjects who presented with clinical malaria (M = blue) and subjects without malaria (NM = red). Subjects who presented with clinical malaria before M20 are represented with green and orange squares. Boxplots with medians, interquartile ranges (IQR), upper whisker as the smallest between maximum × value and Q3 + 1.5*IQR, lower whisker as the largest between minimum × value and Q1 – 1.5*IQR, and log 10 (geometric mean(MFI)) (diamond). Non-parametric tests were used to compare levels with or without clinical malaria (NM vs. M). p -values were adjusted for multiple comparisons, but none was significant. Only p -values
Figure Legend Snippet: Immunogenicity stratified by clinical malaria after M21: total IgG, IgG1-4 subclasses and IgM for CSP NANP at month (M) 20, 21, and 32 for RTS,S/AS01 vaccinees with (R3R) and without (R3C) booster, and comparator (C3C). Stratified analysis by malaria after M21, subjects who presented with clinical malaria (M = blue) and subjects without malaria (NM = red). Subjects who presented with clinical malaria before M20 are represented with green and orange squares. Boxplots with medians, interquartile ranges (IQR), upper whisker as the smallest between maximum × value and Q3 + 1.5*IQR, lower whisker as the largest between minimum × value and Q1 – 1.5*IQR, and log 10 (geometric mean(MFI)) (diamond). Non-parametric tests were used to compare levels with or without clinical malaria (NM vs. M). p -values were adjusted for multiple comparisons, but none was significant. Only p -values

Techniques Used: Whisker Assay

Immunogenicity stratified by clinical malaria after M21: total IgG, IgG1-4 subclasses and IgM for CSP FL at month (M) 20, 21, and 32 for RTS,S/AS01 vaccinees with (R3R) and without (R3C) booster, and comparator (C3C). Stratified analysis by malaria after M21, subjects who presented with clinical malaria (M = blue) and subjects without malaria (NM = red). Subjects who presented with clinical malaria before M20 are represented with green and orange squares. Boxplots with medians, interquartile ranges (IQR), upper whisker as the smallest between maximum × value and Q3 + 1.5*IQR, lower whisker as the largest between minimum × value and Q1 – 1.5*IQR, and log 10 (geometric mean(MFI)) (diamond). Non-parametric tests were used to compare levels with or without clinical malaria (NM vs. M). p -values were adjusted for multiple comparisons, but none was significant. Only p -values
Figure Legend Snippet: Immunogenicity stratified by clinical malaria after M21: total IgG, IgG1-4 subclasses and IgM for CSP FL at month (M) 20, 21, and 32 for RTS,S/AS01 vaccinees with (R3R) and without (R3C) booster, and comparator (C3C). Stratified analysis by malaria after M21, subjects who presented with clinical malaria (M = blue) and subjects without malaria (NM = red). Subjects who presented with clinical malaria before M20 are represented with green and orange squares. Boxplots with medians, interquartile ranges (IQR), upper whisker as the smallest between maximum × value and Q3 + 1.5*IQR, lower whisker as the largest between minimum × value and Q1 – 1.5*IQR, and log 10 (geometric mean(MFI)) (diamond). Non-parametric tests were used to compare levels with or without clinical malaria (NM vs. M). p -values were adjusted for multiple comparisons, but none was significant. Only p -values

Techniques Used: Whisker Assay

Immunogenicity for CSP NANP stratified by previous clinical malaria: total IgG, IgG1-4 subclasses and IgM at month (M)20, 21, and 32 for RTS,S/AS01 vaccinees with (R3R) and without (R3C) booster, and comparator (C3C). Stratified analysis by malaria cases before M20, subjects who presented with clinical malaria (M = blue) and subjects without malaria (NM = red). Boxplots with medians, interquartile ranges (IQR), upper whisker as the smallest between maximum × value and Q3 + 1.5*IQR, lower whisker as the largest between minimum × value and Q1 – 1.5*IQR, and log 10 (geometric mean(MFI)) (diamond). Non-parametric tests were used to compare levels with or without clinical malaria (M vs. NM). p -values were adjusted for multiple comparisons, but none was significant. Only p -values
Figure Legend Snippet: Immunogenicity for CSP NANP stratified by previous clinical malaria: total IgG, IgG1-4 subclasses and IgM at month (M)20, 21, and 32 for RTS,S/AS01 vaccinees with (R3R) and without (R3C) booster, and comparator (C3C). Stratified analysis by malaria cases before M20, subjects who presented with clinical malaria (M = blue) and subjects without malaria (NM = red). Boxplots with medians, interquartile ranges (IQR), upper whisker as the smallest between maximum × value and Q3 + 1.5*IQR, lower whisker as the largest between minimum × value and Q1 – 1.5*IQR, and log 10 (geometric mean(MFI)) (diamond). Non-parametric tests were used to compare levels with or without clinical malaria (M vs. NM). p -values were adjusted for multiple comparisons, but none was significant. Only p -values

Techniques Used: Whisker Assay

Antibody responses against the blood stage antigen Rh5 for months (M) 0, 3, 20, 21, and 32 for IgG, IgG1, IgG2, IgG3, IgG4 and IgM. Boxplots with median, interquartile ranges (IQR), upper whisker as the smallest between maximum × value and Q3 + 1.5*IQR and lower whisker as the largest between minimum × value and Q1 – 1.5*IQR. The y -axis is in logarithm 10 scale. Data from months 0 and 3 were obtained from a previous study in the same individuals [7], thus a batch effect might be present. R3R (green): three doses of RTS,S/AS01 E and a RTS,S/AS01 E booster at month 20. R3C (red): three doses of RTS,S/AS01 E and a comparator booster. C3C (blue): three doses of a comparator vaccine and a comparator booster.
Figure Legend Snippet: Antibody responses against the blood stage antigen Rh5 for months (M) 0, 3, 20, 21, and 32 for IgG, IgG1, IgG2, IgG3, IgG4 and IgM. Boxplots with median, interquartile ranges (IQR), upper whisker as the smallest between maximum × value and Q3 + 1.5*IQR and lower whisker as the largest between minimum × value and Q1 – 1.5*IQR. The y -axis is in logarithm 10 scale. Data from months 0 and 3 were obtained from a previous study in the same individuals [7], thus a batch effect might be present. R3R (green): three doses of RTS,S/AS01 E and a RTS,S/AS01 E booster at month 20. R3C (red): three doses of RTS,S/AS01 E and a comparator booster. C3C (blue): three doses of a comparator vaccine and a comparator booster.

Techniques Used: Whisker Assay

Antibody responses against vaccine antigens for months (M) 0, 3, 20, 21, and 32 for IgG, IgG1, and IgG2. Boxplots with median, interquartile ranges (IQR), upper whisker as the smallest between maximum × value and Q3 + 1.5*IQR, and lower whisker as the largest between minimum × value and Q1 – 1.5*IQR. The y -axis is in logarithm 10 scale. Data from months 0 and 3 were obtained from a previous study in the same individuals 7 , thus a batch effect might be present. R3R (green): three doses of RTS,S/AS01 E and a RTS,S/AS01 E booster at month 20. R3C (red): three doses of RTS,S/AS01 E and a comparator booster. C3C (blue): three doses of a comparator vaccine and a comparator booster.
Figure Legend Snippet: Antibody responses against vaccine antigens for months (M) 0, 3, 20, 21, and 32 for IgG, IgG1, and IgG2. Boxplots with median, interquartile ranges (IQR), upper whisker as the smallest between maximum × value and Q3 + 1.5*IQR, and lower whisker as the largest between minimum × value and Q1 – 1.5*IQR. The y -axis is in logarithm 10 scale. Data from months 0 and 3 were obtained from a previous study in the same individuals 7 , thus a batch effect might be present. R3R (green): three doses of RTS,S/AS01 E and a RTS,S/AS01 E booster at month 20. R3C (red): three doses of RTS,S/AS01 E and a comparator booster. C3C (blue): three doses of a comparator vaccine and a comparator booster.

Techniques Used: Whisker Assay

RTS,S/AS01 E booster and long-term immunogenicity against vaccine antigens: total IgG, IgG1-2 subclasses for CSP constructs and HBsAg at month (M) 20, 21, and 32 for RTS,S/AS01 vaccinees with (R3R) and without (R3C) booster, and comparator (C3C). Boxplots with medians, interquartile ranges (IQR), upper whisker as the smallest between maximum × value and Q3 + 1.5*IQR, lower whisker as the largest between minimum × value and Q1 – 1.5*IQR, and log 10 (geometric mean(MFI)) (diamond). Non-parametric tests were used to compare the booster response (M20 vs. M21) and the long-term immunogenicity (M21 vs. M32), as well as to compare the R3C and R3R groups at each timepoint. Only p -values
Figure Legend Snippet: RTS,S/AS01 E booster and long-term immunogenicity against vaccine antigens: total IgG, IgG1-2 subclasses for CSP constructs and HBsAg at month (M) 20, 21, and 32 for RTS,S/AS01 vaccinees with (R3R) and without (R3C) booster, and comparator (C3C). Boxplots with medians, interquartile ranges (IQR), upper whisker as the smallest between maximum × value and Q3 + 1.5*IQR, lower whisker as the largest between minimum × value and Q1 – 1.5*IQR, and log 10 (geometric mean(MFI)) (diamond). Non-parametric tests were used to compare the booster response (M20 vs. M21) and the long-term immunogenicity (M21 vs. M32), as well as to compare the R3C and R3R groups at each timepoint. Only p -values

Techniques Used: Construct, Whisker Assay

RTS,S/AS01 E booster and long-term immunogenicity against vaccine antigens: IgG3-4 subclasses and IgM for CSP constructs and HBsAg at month (M) 20, 21, and 32 for RTS,S/AS01 vaccinees with (R3R) and without (R3C) booster, and comparator (C3C). Boxplots with medians, interquartile ranges (IQR), upper whisker as the smallest between maximum × value and Q3 + 1.5*IQR, lower whisker as the largest between minimum × value and Q1 – 1.5*IQR, and log 10 (geometric mean(MFI)) (diamond). Non-parametric tests were used to compare the booster response (M20 vs. M21) and the long-term immunogenicity (M21 vs. M32), as well as to compare the R3C and R3R groups at each timepoint. Only p -values
Figure Legend Snippet: RTS,S/AS01 E booster and long-term immunogenicity against vaccine antigens: IgG3-4 subclasses and IgM for CSP constructs and HBsAg at month (M) 20, 21, and 32 for RTS,S/AS01 vaccinees with (R3R) and without (R3C) booster, and comparator (C3C). Boxplots with medians, interquartile ranges (IQR), upper whisker as the smallest between maximum × value and Q3 + 1.5*IQR, lower whisker as the largest between minimum × value and Q1 – 1.5*IQR, and log 10 (geometric mean(MFI)) (diamond). Non-parametric tests were used to compare the booster response (M20 vs. M21) and the long-term immunogenicity (M21 vs. M32), as well as to compare the R3C and R3R groups at each timepoint. Only p -values

Techniques Used: Construct, Whisker Assay

RTS,S/AS01 E booster and long-term immunogenicity against the blood stage antigen Rh5: total IgG, IgG1-4 subclasses and IgM at month (M) 20, 21, and 32 for RTS,S/AS01 vaccinees with (R3R) and without (R3C) booster, and comparator (C3C). Boxplots with medians, interquartile ranges (IQR), upper whisker as the smallest between maximum × value and Q3 + 1.5*IQR, lower whisker as the largest between minimum × value and Q1 – 1.5*IQR, and log 10 (geometric mean(MFI)) (diamond). Non-parametric tests were used to compare the booster response (M20 vs. M21) and the long-term immunogenicity (M21 vs. M32), as well as to compare the R3C and R3R groups at each timepoint. Only p -values
Figure Legend Snippet: RTS,S/AS01 E booster and long-term immunogenicity against the blood stage antigen Rh5: total IgG, IgG1-4 subclasses and IgM at month (M) 20, 21, and 32 for RTS,S/AS01 vaccinees with (R3R) and without (R3C) booster, and comparator (C3C). Boxplots with medians, interquartile ranges (IQR), upper whisker as the smallest between maximum × value and Q3 + 1.5*IQR, lower whisker as the largest between minimum × value and Q1 – 1.5*IQR, and log 10 (geometric mean(MFI)) (diamond). Non-parametric tests were used to compare the booster response (M20 vs. M21) and the long-term immunogenicity (M21 vs. M32), as well as to compare the R3C and R3R groups at each timepoint. Only p -values

Techniques Used: Whisker Assay

Antibody responses against vaccine antigens for months (M) 0, 3, 20, 21, and 32 for IgG3, IgG4 and IgM. Boxplots with median, interquartile ranges (IQR), upper whisker as the smallest between maximum × value and Q3 + 1.5*IQR, and lower whisker as the largest between minimum × value and Q1 – 1.5*IQR. The y -axis is in logarithm 10 scale. Data from months 0 and 3 were obtained from a previous study in the same individuals [7], thus a batch effect might be present. R3R (green): three doses of RTS,S/AS01 E and a RTS,S/AS01 E booster at month 20. R3C (red): three doses of RTS,S/AS01 E and a comparator booster. C3C (blue): three doses of a comparator vaccine and a comparator booster.
Figure Legend Snippet: Antibody responses against vaccine antigens for months (M) 0, 3, 20, 21, and 32 for IgG3, IgG4 and IgM. Boxplots with median, interquartile ranges (IQR), upper whisker as the smallest between maximum × value and Q3 + 1.5*IQR, and lower whisker as the largest between minimum × value and Q1 – 1.5*IQR. The y -axis is in logarithm 10 scale. Data from months 0 and 3 were obtained from a previous study in the same individuals [7], thus a batch effect might be present. R3R (green): three doses of RTS,S/AS01 E and a RTS,S/AS01 E booster at month 20. R3C (red): three doses of RTS,S/AS01 E and a comparator booster. C3C (blue): three doses of a comparator vaccine and a comparator booster.

Techniques Used: Whisker Assay

Immunogenicity for CSP C-term stratified by previous clinical malaria: total IgG, IgG1-4 subclasses and IgM at month (M)20, 21, and 32 for RTS,S/AS01 vaccinees with (R3R) and without (R3C) booster, and comparator (C3C). Stratified analysis by malaria cases before M20, subjects who presented with clinical malaria (M = blue) and subjects without malaria (NM = red). Boxplots with medians, interquartile ranges (IQR), upper whisker as the smallest between maximum × value and Q3 + 1.5*IQR, lower whisker as the largest between minimum × value and Q1 – 1.5*IQR, and log 10 (geometric mean(MFI)) (diamond). Non-parametric tests were used to compare levels with or without clinical malaria (M vs. NM). p -values were adjusted for multiple comparisons, but none was significant. Only p -values
Figure Legend Snippet: Immunogenicity for CSP C-term stratified by previous clinical malaria: total IgG, IgG1-4 subclasses and IgM at month (M)20, 21, and 32 for RTS,S/AS01 vaccinees with (R3R) and without (R3C) booster, and comparator (C3C). Stratified analysis by malaria cases before M20, subjects who presented with clinical malaria (M = blue) and subjects without malaria (NM = red). Boxplots with medians, interquartile ranges (IQR), upper whisker as the smallest between maximum × value and Q3 + 1.5*IQR, lower whisker as the largest between minimum × value and Q1 – 1.5*IQR, and log 10 (geometric mean(MFI)) (diamond). Non-parametric tests were used to compare levels with or without clinical malaria (M vs. NM). p -values were adjusted for multiple comparisons, but none was significant. Only p -values

Techniques Used: Whisker Assay

27) Product Images from "Long-term exposure to Myozyme results in a decrease of anti-drug antibodies in late-onset Pompe disease patients"

Article Title: Long-term exposure to Myozyme results in a decrease of anti-drug antibodies in late-onset Pompe disease patients

Journal: Scientific Reports

doi: 10.1038/srep36182

Anti-rhGAA IgG1 and IgG4 are the most prevalent subclasses of antibodies developed in response to long-term ERT. ( A – F ) Anti-rhGAA antibodies measured with a capture assay specific for IgG1, IgG2, IgG3, IgG4, IgM, and IgE antibodies. Estimated antibody concentrations are reported for each subject. Average and standard deviation are indicated for each of the study cohorts: LOPD subjects receiving ERT (Treated, n = 28), untreated LOPD subjects (Untreated, n = 10), and healthy donors (HD, n = 43). Unpaired two-tailed t-test was used to compare results across the study cohorts (**P
Figure Legend Snippet: Anti-rhGAA IgG1 and IgG4 are the most prevalent subclasses of antibodies developed in response to long-term ERT. ( A – F ) Anti-rhGAA antibodies measured with a capture assay specific for IgG1, IgG2, IgG3, IgG4, IgM, and IgE antibodies. Estimated antibody concentrations are reported for each subject. Average and standard deviation are indicated for each of the study cohorts: LOPD subjects receiving ERT (Treated, n = 28), untreated LOPD subjects (Untreated, n = 10), and healthy donors (HD, n = 43). Unpaired two-tailed t-test was used to compare results across the study cohorts (**P

Techniques Used: Standard Deviation, Two Tailed Test

28) Product Images from "Profiling of microorganism-binding serum antibody specificities in professional athletes"

Article Title: Profiling of microorganism-binding serum antibody specificities in professional athletes

Journal: PLoS ONE

doi: 10.1371/journal.pone.0203665

Graphic representation showing correlation coefficients obtained by correlating the string of reactivity of serumtotal IgG and total IgA with IgG subclasses, for different microorganisms in professional athletes. A) Escherichia coli ATCC25922; B) Candida albicans ATCC 10259; C) Lactobacillus plantarum WCFS1; D) Salmonella typhimurium 2865; E) Lactobacillusrhamnosus LGG, F) LPS from E . coli O55:B5.
Figure Legend Snippet: Graphic representation showing correlation coefficients obtained by correlating the string of reactivity of serumtotal IgG and total IgA with IgG subclasses, for different microorganisms in professional athletes. A) Escherichia coli ATCC25922; B) Candida albicans ATCC 10259; C) Lactobacillus plantarum WCFS1; D) Salmonella typhimurium 2865; E) Lactobacillusrhamnosus LGG, F) LPS from E . coli O55:B5.

Techniques Used:

Analysis of reactivity of serial dilutions of serum IgG in A) professional athletes; B) control group, and of serum IgA in C) professional athletes; D) control group to different microorganisms. Red colour– E . coli ATCC25922; black - C . albicans ATCC 10259; turquoise– L . plantarum WCFS1; green– S . typhimurium 2865; blue— L . rhamnosus LGG, violet—LPS from E . coli 055:B5.
Figure Legend Snippet: Analysis of reactivity of serial dilutions of serum IgG in A) professional athletes; B) control group, and of serum IgA in C) professional athletes; D) control group to different microorganisms. Red colour– E . coli ATCC25922; black - C . albicans ATCC 10259; turquoise– L . plantarum WCFS1; green– S . typhimurium 2865; blue— L . rhamnosus LGG, violet—LPS from E . coli 055:B5.

Techniques Used:

The strings of reactivities (apsorbance) of IgG and IgA to bacteria from different individuals were correlated, and the Pearson product-moment correlation coefficientswereplotted for individual bacteria. Red colour- Professional athletes PA; Green colour–Control.
Figure Legend Snippet: The strings of reactivities (apsorbance) of IgG and IgA to bacteria from different individuals were correlated, and the Pearson product-moment correlation coefficientswereplotted for individual bacteria. Red colour- Professional athletes PA; Green colour–Control.

Techniques Used:

29) Product Images from "Human Cytomegalovirus Inhibits Erythropoietin Production"

Article Title: Human Cytomegalovirus Inhibits Erythropoietin Production

Journal: Journal of the American Society of Nephrology : JASN

doi: 10.1681/ASN.2013101125

Kidney tissue biopsy specimens from patients with CKD are positive for hCMV, and blood hCMV IgG levels inversely correlate with red blood cell count. (A) Biopsy specimens from CKD were stained for hCMV IE proteins; arrows highlight examples of positive
Figure Legend Snippet: Kidney tissue biopsy specimens from patients with CKD are positive for hCMV, and blood hCMV IgG levels inversely correlate with red blood cell count. (A) Biopsy specimens from CKD were stained for hCMV IE proteins; arrows highlight examples of positive

Techniques Used: Cell Counting, Staining

30) Product Images from "The Specificity of Targeted Vaccines for APC Surface Molecules Influences the Immune Response Phenotype"

Article Title: The Specificity of Targeted Vaccines for APC Surface Molecules Influences the Immune Response Phenotype

Journal: PLoS ONE

doi: 10.1371/journal.pone.0080008

Antibody and T cell responses following vaccination with OVA targeted to MHC class II molecules or CCR1/3/5. (a,b) Supernatants of 293E cells transfected with the indicated plasmids were tested for secreted proteins in ELISA (a) and examined by Western blotting with anti-OVA mAb under reducing (+ME) or non-reducing (-ME) conditions (b). Vaccine proteins are indicated below lanes. (c-f) Mice were immunized once i.d. with 25 µg DNA/EP, as indicated. (c-e) Sera were assayed for total IgG (c), IgG1 (d) or IgG2a (e) against OVA. (f) Splenocytes collected at day 14 post immunization were stimulated in vitro with OVA protein or controls as indicated, and analyzed by an IFNγ EliSpot. *indicates p
Figure Legend Snippet: Antibody and T cell responses following vaccination with OVA targeted to MHC class II molecules or CCR1/3/5. (a,b) Supernatants of 293E cells transfected with the indicated plasmids were tested for secreted proteins in ELISA (a) and examined by Western blotting with anti-OVA mAb under reducing (+ME) or non-reducing (-ME) conditions (b). Vaccine proteins are indicated below lanes. (c-f) Mice were immunized once i.d. with 25 µg DNA/EP, as indicated. (c-e) Sera were assayed for total IgG (c), IgG1 (d) or IgG2a (e) against OVA. (f) Splenocytes collected at day 14 post immunization were stimulated in vitro with OVA protein or controls as indicated, and analyzed by an IFNγ EliSpot. *indicates p

Techniques Used: Transfection, Enzyme-linked Immunosorbent Assay, Western Blot, Mouse Assay, In Vitro, Enzyme-linked Immunospot

31) Product Images from "Fluorescent-Magnetic-Biotargeting Multifunctional Nanobioprobes for Detecting and Isolating Multiple Types of Tumor Cells"

Article Title: Fluorescent-Magnetic-Biotargeting Multifunctional Nanobioprobes for Detecting and Isolating Multiple Types of Tumor Cells

Journal: ACS nano

doi: 10.1021/nn1011336

(A) Schematic drawing of a mAb-coupled FMBMN. Fuorescent-magnetic bifunctional nanoparticles were covalently coupled with avidin. They were then coated with biotinylated goat anti-mouse IgG (Fc specific) via the biotin-avidin interaction. Mouse monoclonal
Figure Legend Snippet: (A) Schematic drawing of a mAb-coupled FMBMN. Fuorescent-magnetic bifunctional nanoparticles were covalently coupled with avidin. They were then coated with biotinylated goat anti-mouse IgG (Fc specific) via the biotin-avidin interaction. Mouse monoclonal

Techniques Used: Avidin-Biotin Assay

32) Product Images from "Evaluation of Wuchereria bancrofti GST as a Vaccine Candidate for Lymphatic Filariasis"

Article Title: Evaluation of Wuchereria bancrofti GST as a Vaccine Candidate for Lymphatic Filariasis

Journal: PLoS Neglected Tropical Diseases

doi: 10.1371/journal.pntd.0000457

Subclass specific anti-WbGST IgG antibodies in the sera of mice immunized with rWbGST protein. Subclass analysis was performed using a mouse antibody isotyping ELISA kit. The bars represent the mean O.D.±SD at 405 nm of five mice per group.
Figure Legend Snippet: Subclass specific anti-WbGST IgG antibodies in the sera of mice immunized with rWbGST protein. Subclass analysis was performed using a mouse antibody isotyping ELISA kit. The bars represent the mean O.D.±SD at 405 nm of five mice per group.

Techniques Used: Mouse Assay, Enzyme-linked Immunosorbent Assay

Human immune responses to WbGST. A. Immunoreactivity of rWbGST with sera from different clinical groups of bancroftian filariasis. Approximately 1 µg of rWbGST was resolved on 15% SDS-PAGE, transferred to nitrocellulose membrane and blots were probed with pooled sera from MF, CP, EN or NEN individuals. Results showed strong immunoreactivity with pooled EN sera followed by CP and MF but no reactivity was detected with control NEN sera. Data is representative of one of three experiments using the same sera samples. B. Humoral immune response to rWbGST in human subjects. Total IgG levels against rWbGST in various clinical groups were evaluated by ELISA. Each data point represents single individual absorbance from the four different groups. Horizontal lines represent geometric mean value of EN (43), Mf (45), CP (45) and NEN (39) samples respectively. C. WbGST-specific IgG subclasses in the sera from different clinical groups. Isotype of anti-WbGST IgG antibodies in the sera from various groups of human subjects (EN, MF, CP, TPE and NEN) were evaluated using an isotype-specific ELISA. Data presented is mean±SD value from EN (43), Mf (45), CP (45) and NEN (39). * Significant (p
Figure Legend Snippet: Human immune responses to WbGST. A. Immunoreactivity of rWbGST with sera from different clinical groups of bancroftian filariasis. Approximately 1 µg of rWbGST was resolved on 15% SDS-PAGE, transferred to nitrocellulose membrane and blots were probed with pooled sera from MF, CP, EN or NEN individuals. Results showed strong immunoreactivity with pooled EN sera followed by CP and MF but no reactivity was detected with control NEN sera. Data is representative of one of three experiments using the same sera samples. B. Humoral immune response to rWbGST in human subjects. Total IgG levels against rWbGST in various clinical groups were evaluated by ELISA. Each data point represents single individual absorbance from the four different groups. Horizontal lines represent geometric mean value of EN (43), Mf (45), CP (45) and NEN (39) samples respectively. C. WbGST-specific IgG subclasses in the sera from different clinical groups. Isotype of anti-WbGST IgG antibodies in the sera from various groups of human subjects (EN, MF, CP, TPE and NEN) were evaluated using an isotype-specific ELISA. Data presented is mean±SD value from EN (43), Mf (45), CP (45) and NEN (39). * Significant (p

Techniques Used: SDS Page, Enzyme-linked Immunosorbent Assay

33) Product Images from "Profiling of microorganism-binding serum antibody specificities in professional athletes"

Article Title: Profiling of microorganism-binding serum antibody specificities in professional athletes

Journal: PLoS ONE

doi: 10.1371/journal.pone.0203665

Graphic representation showing correlation coefficients obtained by correlating the string of reactivity of serum IgG ofdifferent individuals to different microorganism, obtained in ELISA, at steady state. A) Professional athletes; B) Control group. Red colour–Pearson product-moment correlation coefficient, r = 1, Blue– r = -1.
Figure Legend Snippet: Graphic representation showing correlation coefficients obtained by correlating the string of reactivity of serum IgG ofdifferent individuals to different microorganism, obtained in ELISA, at steady state. A) Professional athletes; B) Control group. Red colour–Pearson product-moment correlation coefficient, r = 1, Blue– r = -1.

Techniques Used: Enzyme-linked Immunosorbent Assay

Graphic representation showing correlation coefficients obtained by correlating the string of reactivity of serumtotal IgG and total IgA with IgG subclasses, for different microorganisms in professional athletes. A) Escherichia coli ATCC25922; B) Candida albicans ATCC 10259; C) Lactobacillus plantarum WCFS1; D) Salmonella typhimurium 2865; E) Lactobacillusrhamnosus LGG, F) LPS from E . coli O55:B5.
Figure Legend Snippet: Graphic representation showing correlation coefficients obtained by correlating the string of reactivity of serumtotal IgG and total IgA with IgG subclasses, for different microorganisms in professional athletes. A) Escherichia coli ATCC25922; B) Candida albicans ATCC 10259; C) Lactobacillus plantarum WCFS1; D) Salmonella typhimurium 2865; E) Lactobacillusrhamnosus LGG, F) LPS from E . coli O55:B5.

Techniques Used:

Analysis of reactivity of serial dilutions of serum IgG in A) professional athletes; B) control group, and of serum IgA in C) professional athletes; D) control group to different microorganisms. Red colour– E . coli ATCC25922; black - C . albicans ATCC 10259; turquoise– L . plantarum WCFS1; green– S . typhimurium 2865; blue— L . rhamnosus LGG, violet—LPS from E . coli 055:B5.
Figure Legend Snippet: Analysis of reactivity of serial dilutions of serum IgG in A) professional athletes; B) control group, and of serum IgA in C) professional athletes; D) control group to different microorganisms. Red colour– E . coli ATCC25922; black - C . albicans ATCC 10259; turquoise– L . plantarum WCFS1; green– S . typhimurium 2865; blue— L . rhamnosus LGG, violet—LPS from E . coli 055:B5.

Techniques Used:

The strings of reactivities (apsorbance) of IgG and IgA to bacteria from different individuals were correlated, and the Pearson product-moment correlation coefficientswereplotted for individual bacteria. Red colour- Professional athletes PA; Green colour–Control.
Figure Legend Snippet: The strings of reactivities (apsorbance) of IgG and IgA to bacteria from different individuals were correlated, and the Pearson product-moment correlation coefficientswereplotted for individual bacteria. Red colour- Professional athletes PA; Green colour–Control.

Techniques Used:

34) Product Images from "Role of specific IgE, IgG and IgG4 antibodies to corn dust in exposed workers"

Article Title: Role of specific IgE, IgG and IgG4 antibodies to corn dust in exposed workers

Journal: The Korean Journal of Internal Medicine

doi: 10.3904/kjim.1998.13.2.88

Comparison of serum specific IgG and IgG4 antibodies to corn dust in 43 exposed workers and unexposed controls. I: Low exposure, II: Intermediate exposure, III: High exposure
Figure Legend Snippet: Comparison of serum specific IgG and IgG4 antibodies to corn dust in 43 exposed workers and unexposed controls. I: Low exposure, II: Intermediate exposure, III: High exposure

Techniques Used:

Correlation between specific IgG to corn dust and exposure duration. A statistical significance was noted (r=0.36, p=0.02).
Figure Legend Snippet: Correlation between specific IgG to corn dust and exposure duration. A statistical significance was noted (r=0.36, p=0.02).

Techniques Used:

35) Product Images from "Biochemical Characterization and Evaluation of a Brugia malayi Small Heat Shock Protein as a Vaccine against Lymphatic Filariasis"

Article Title: Biochemical Characterization and Evaluation of a Brugia malayi Small Heat Shock Protein as a Vaccine against Lymphatic Filariasis

Journal: PLoS ONE

doi: 10.1371/journal.pone.0034077

Isotype of anti-BmHsp12.6 IgG antibodies in the sera of mice. Mice were immunized with A ) BmHsp12.6, B ) BmHsp12.6αc or C ) N-BmHsp12.6 using homologous DNA vaccine regimen or a heterologous prime boost approach. Control mice were immunized with vector alone or adjuvant. Isotype specific ELISA was performed as described in the methods section. Bars represent mean O.D ± SD from five mice per group. * Significant (p
Figure Legend Snippet: Isotype of anti-BmHsp12.6 IgG antibodies in the sera of mice. Mice were immunized with A ) BmHsp12.6, B ) BmHsp12.6αc or C ) N-BmHsp12.6 using homologous DNA vaccine regimen or a heterologous prime boost approach. Control mice were immunized with vector alone or adjuvant. Isotype specific ELISA was performed as described in the methods section. Bars represent mean O.D ± SD from five mice per group. * Significant (p

Techniques Used: Mouse Assay, Plasmid Preparation, Enzyme-linked Immunosorbent Assay

Titer of IgG antibodies. Mice were immunized with A ) BmHsp12.6, B ) BmHsp12.6αc or C ) N-BmHsp12.6 using homologous DNA vaccine regimen or a heterologous prime boost approach. Approximately, 100 ng of peptides or proteins respectively (100 ng/100 µl/well) were coated on to the wells of an ELISA plate and bound serum IgG was detected using an HRP-labeled anti-mouse IgG secondary antibody. Each data point indicates mean (± S.D) value from five animals.
Figure Legend Snippet: Titer of IgG antibodies. Mice were immunized with A ) BmHsp12.6, B ) BmHsp12.6αc or C ) N-BmHsp12.6 using homologous DNA vaccine regimen or a heterologous prime boost approach. Approximately, 100 ng of peptides or proteins respectively (100 ng/100 µl/well) were coated on to the wells of an ELISA plate and bound serum IgG was detected using an HRP-labeled anti-mouse IgG secondary antibody. Each data point indicates mean (± S.D) value from five animals.

Techniques Used: Mouse Assay, Enzyme-linked Immunosorbent Assay, Labeling

Anti-rBmHsp12.6 IgG antibody isotypes in the human sera. IgG isotype antibodies against ( A ) rBmHsp12.6 protein, ( B ) BmHsp12.6αc peptide or ( C ) N-BmHsp12.6 in the sera of EN, MF, CP and NEN subjects were measured using an indirect ELISA. A total of 20 sera samples were evaluated from EN, MF, and CP from NEN. Each data point represents sera sample from a single individual. Each bar represents the mean ± SD of five patients from each group. * Significant (p
Figure Legend Snippet: Anti-rBmHsp12.6 IgG antibody isotypes in the human sera. IgG isotype antibodies against ( A ) rBmHsp12.6 protein, ( B ) BmHsp12.6αc peptide or ( C ) N-BmHsp12.6 in the sera of EN, MF, CP and NEN subjects were measured using an indirect ELISA. A total of 20 sera samples were evaluated from EN, MF, and CP from NEN. Each data point represents sera sample from a single individual. Each bar represents the mean ± SD of five patients from each group. * Significant (p

Techniques Used: Indirect ELISA

Anti-rBmHsp12.6 IgG antibody levels in the sera of human. Levels of total IgG antibodies against ( A ) rBmHsp12.6 protein, ( B ) BmHsp12.6αc peptide or ( C ) N-BmHsp12.6 peptide in the sera of EN, MF, CP and NEN subjects were measured using an indirect ELISA. A total of 20 sera samples were evaluated from EN, MF, and CP and 10 samples from NEN. Each data point represents sera sample from a single individual. Horizontal lines represent geometric mean value. Data is represented as scatter plot where each dot represents absorbance of individual sera.
Figure Legend Snippet: Anti-rBmHsp12.6 IgG antibody levels in the sera of human. Levels of total IgG antibodies against ( A ) rBmHsp12.6 protein, ( B ) BmHsp12.6αc peptide or ( C ) N-BmHsp12.6 peptide in the sera of EN, MF, CP and NEN subjects were measured using an indirect ELISA. A total of 20 sera samples were evaluated from EN, MF, and CP and 10 samples from NEN. Each data point represents sera sample from a single individual. Horizontal lines represent geometric mean value. Data is represented as scatter plot where each dot represents absorbance of individual sera.

Techniques Used: Indirect ELISA

36) Product Images from "Biochemical Characterization and Evaluation of a Brugia malayi Small Heat Shock Protein as a Vaccine against Lymphatic Filariasis"

Article Title: Biochemical Characterization and Evaluation of a Brugia malayi Small Heat Shock Protein as a Vaccine against Lymphatic Filariasis

Journal: PLoS ONE

doi: 10.1371/journal.pone.0034077

Titer of IgG antibodies. Mice were immunized with A ) BmHsp12.6, B ) BmHsp12.6αc or C ) N-BmHsp12.6 using homologous DNA vaccine regimen or a heterologous prime boost approach. Approximately, 100 ng of peptides or proteins respectively (100 ng/100 µl/well) were coated on to the wells of an ELISA plate and bound serum IgG was detected using an HRP-labeled anti-mouse IgG secondary antibody. Each data point indicates mean (± S.D) value from five animals.
Figure Legend Snippet: Titer of IgG antibodies. Mice were immunized with A ) BmHsp12.6, B ) BmHsp12.6αc or C ) N-BmHsp12.6 using homologous DNA vaccine regimen or a heterologous prime boost approach. Approximately, 100 ng of peptides or proteins respectively (100 ng/100 µl/well) were coated on to the wells of an ELISA plate and bound serum IgG was detected using an HRP-labeled anti-mouse IgG secondary antibody. Each data point indicates mean (± S.D) value from five animals.

Techniques Used: Mouse Assay, Enzyme-linked Immunosorbent Assay, Labeling

37) Product Images from "Genome of the human hookworm Necator americanus"

Article Title: Genome of the human hookworm Necator americanus

Journal: Nature genetics

doi: 10.1038/ng.2875

The serum responses to Necator americanus antigens vary with age and infection intensity The heat map shows the immunoreactivity of 22 antigens to the IgG antibodies from groups of uninfected individuals, infected children (HW
Figure Legend Snippet: The serum responses to Necator americanus antigens vary with age and infection intensity The heat map shows the immunoreactivity of 22 antigens to the IgG antibodies from groups of uninfected individuals, infected children (HW

Techniques Used: Infection

38) Product Images from "Cellular and Humoral Immunity following Snow Mountain Virus Challenge"

Article Title: Cellular and Humoral Immunity following Snow Mountain Virus Challenge

Journal:

doi: 10.1128/JVI.79.5.2900-2909.2005

SMV elicits a cross-reactive serum IgG response in challenged volunteers. Pre- and postchallenge sera from each volunteer were tested for anti-SMV, anti-HV, and anti-NV IgG by ELISA. *, P
Figure Legend Snippet: SMV elicits a cross-reactive serum IgG response in challenged volunteers. Pre- and postchallenge sera from each volunteer were tested for anti-SMV, anti-HV, and anti-NV IgG by ELISA. *, P

Techniques Used: Enzyme-linked Immunosorbent Assay

39) Product Images from "Antibody responses to the RTS,S/AS01E vaccine and Plasmodium falciparum antigens after a booster dose within the phase 3 trial in Mozambique"

Article Title: Antibody responses to the RTS,S/AS01E vaccine and Plasmodium falciparum antigens after a booster dose within the phase 3 trial in Mozambique

Journal: NPJ Vaccines

doi: 10.1038/s41541-020-0192-7

Immunogenicity stratified by clinical malaria after M21: total IgG, IgG1-4 subclasses and IgM for CSP C-term at month (M) 20, 21, and 32 for RTS,S/AS01 vaccinees with (R3R) and without (R3C) booster, and comparator (C3C). Stratified analysis by malaria after M21, subjects who presented with clinical malaria (M = blue) and subjects without malaria (NM = red). Subjects who presented with clinical malaria before M20 are represented with green and orange squares. Boxplots with medians, interquartile ranges (IQR), upper whisker as the smallest between maximum × value and Q3 + 1.5*IQR, lower whisker as the largest between minimum × value and Q1 – 1.5*IQR, and log 10 (geometric mean(MFI)) (diamond). Non-parametric tests were used to compare levels with or without clinical malaria (NM vs. M). p -values were adjusted for multiple comparisons, but none was significant. Only p -values
Figure Legend Snippet: Immunogenicity stratified by clinical malaria after M21: total IgG, IgG1-4 subclasses and IgM for CSP C-term at month (M) 20, 21, and 32 for RTS,S/AS01 vaccinees with (R3R) and without (R3C) booster, and comparator (C3C). Stratified analysis by malaria after M21, subjects who presented with clinical malaria (M = blue) and subjects without malaria (NM = red). Subjects who presented with clinical malaria before M20 are represented with green and orange squares. Boxplots with medians, interquartile ranges (IQR), upper whisker as the smallest between maximum × value and Q3 + 1.5*IQR, lower whisker as the largest between minimum × value and Q1 – 1.5*IQR, and log 10 (geometric mean(MFI)) (diamond). Non-parametric tests were used to compare levels with or without clinical malaria (NM vs. M). p -values were adjusted for multiple comparisons, but none was significant. Only p -values

Techniques Used: Whisker Assay

Immunogenicity stratified by clinical malaria after M21: total IgG, IgG1-4 subclasses and IgM for HBsAg at month (M) 20, 21, and 32 for RTS,S/AS01 vaccinees with (R3R) and without (R3C) booster, and comparator (C3C). Stratified analysis by malaria after M21, subjects who presented with clinical malaria (M = blue) and subjects without malaria (NM = red). Subjects who presented with clinical malaria before M20 are represented with green and orange squares. Boxplots with medians, interquartile ranges (IQR), upper whisker as the smallest between maximum × value and Q3 + 1.5*IQR, lower whisker as the largest between minimum × value and Q1 – 1.5*IQR, and log 10 (geometric mean(MFI)) (diamond). Non-parametric tests were used to compare levels with or without clinical malaria (NM vs. M). p -values were adjusted for multiple comparisons, but none was significant. Only p -values
Figure Legend Snippet: Immunogenicity stratified by clinical malaria after M21: total IgG, IgG1-4 subclasses and IgM for HBsAg at month (M) 20, 21, and 32 for RTS,S/AS01 vaccinees with (R3R) and without (R3C) booster, and comparator (C3C). Stratified analysis by malaria after M21, subjects who presented with clinical malaria (M = blue) and subjects without malaria (NM = red). Subjects who presented with clinical malaria before M20 are represented with green and orange squares. Boxplots with medians, interquartile ranges (IQR), upper whisker as the smallest between maximum × value and Q3 + 1.5*IQR, lower whisker as the largest between minimum × value and Q1 – 1.5*IQR, and log 10 (geometric mean(MFI)) (diamond). Non-parametric tests were used to compare levels with or without clinical malaria (NM vs. M). p -values were adjusted for multiple comparisons, but none was significant. Only p -values

Techniques Used: Whisker Assay

Immunogenicity for CSP FL stratified by previous clinical malaria: total IgG, IgG1-4 subclasses and IgM at month (M)20, 21, and 32 for RTS,S/AS01 vaccinees with (R3R) and without (R3C) booster, and comparator (C3C). Stratified analysis by malaria cases before M20, subjects who presented with clinical malaria (M = blue) and subjects without malaria (NM = red). Boxplots with medians, interquartile ranges (IQR), upper whisker as the smallest between maximum × value and Q3 + 1.5*IQR, lower whisker as the largest between minimum × value and Q1 – 1.5*IQR, and log 10 (geometric mean(MFI)) (diamond). Non-parametric tests were used to compare levels with or without clinical malaria (M vs. NM). p -values were adjusted for multiple comparisons, but none was significant. Only p -values
Figure Legend Snippet: Immunogenicity for CSP FL stratified by previous clinical malaria: total IgG, IgG1-4 subclasses and IgM at month (M)20, 21, and 32 for RTS,S/AS01 vaccinees with (R3R) and without (R3C) booster, and comparator (C3C). Stratified analysis by malaria cases before M20, subjects who presented with clinical malaria (M = blue) and subjects without malaria (NM = red). Boxplots with medians, interquartile ranges (IQR), upper whisker as the smallest between maximum × value and Q3 + 1.5*IQR, lower whisker as the largest between minimum × value and Q1 – 1.5*IQR, and log 10 (geometric mean(MFI)) (diamond). Non-parametric tests were used to compare levels with or without clinical malaria (M vs. NM). p -values were adjusted for multiple comparisons, but none was significant. Only p -values

Techniques Used: Whisker Assay

Immunogenicity stratified by clinical malaria after M21: total IgG, IgG1-4 subclasses and IgM for CSP NANP at month (M) 20, 21, and 32 for RTS,S/AS01 vaccinees with (R3R) and without (R3C) booster, and comparator (C3C). Stratified analysis by malaria after M21, subjects who presented with clinical malaria (M = blue) and subjects without malaria (NM = red). Subjects who presented with clinical malaria before M20 are represented with green and orange squares. Boxplots with medians, interquartile ranges (IQR), upper whisker as the smallest between maximum × value and Q3 + 1.5*IQR, lower whisker as the largest between minimum × value and Q1 – 1.5*IQR, and log 10 (geometric mean(MFI)) (diamond). Non-parametric tests were used to compare levels with or without clinical malaria (NM vs. M). p -values were adjusted for multiple comparisons, but none was significant. Only p -values
Figure Legend Snippet: Immunogenicity stratified by clinical malaria after M21: total IgG, IgG1-4 subclasses and IgM for CSP NANP at month (M) 20, 21, and 32 for RTS,S/AS01 vaccinees with (R3R) and without (R3C) booster, and comparator (C3C). Stratified analysis by malaria after M21, subjects who presented with clinical malaria (M = blue) and subjects without malaria (NM = red). Subjects who presented with clinical malaria before M20 are represented with green and orange squares. Boxplots with medians, interquartile ranges (IQR), upper whisker as the smallest between maximum × value and Q3 + 1.5*IQR, lower whisker as the largest between minimum × value and Q1 – 1.5*IQR, and log 10 (geometric mean(MFI)) (diamond). Non-parametric tests were used to compare levels with or without clinical malaria (NM vs. M). p -values were adjusted for multiple comparisons, but none was significant. Only p -values

Techniques Used: Whisker Assay

Immunogenicity stratified by clinical malaria after M21: total IgG, IgG1-4 subclasses and IgM for CSP FL at month (M) 20, 21, and 32 for RTS,S/AS01 vaccinees with (R3R) and without (R3C) booster, and comparator (C3C). Stratified analysis by malaria after M21, subjects who presented with clinical malaria (M = blue) and subjects without malaria (NM = red). Subjects who presented with clinical malaria before M20 are represented with green and orange squares. Boxplots with medians, interquartile ranges (IQR), upper whisker as the smallest between maximum × value and Q3 + 1.5*IQR, lower whisker as the largest between minimum × value and Q1 – 1.5*IQR, and log 10 (geometric mean(MFI)) (diamond). Non-parametric tests were used to compare levels with or without clinical malaria (NM vs. M). p -values were adjusted for multiple comparisons, but none was significant. Only p -values
Figure Legend Snippet: Immunogenicity stratified by clinical malaria after M21: total IgG, IgG1-4 subclasses and IgM for CSP FL at month (M) 20, 21, and 32 for RTS,S/AS01 vaccinees with (R3R) and without (R3C) booster, and comparator (C3C). Stratified analysis by malaria after M21, subjects who presented with clinical malaria (M = blue) and subjects without malaria (NM = red). Subjects who presented with clinical malaria before M20 are represented with green and orange squares. Boxplots with medians, interquartile ranges (IQR), upper whisker as the smallest between maximum × value and Q3 + 1.5*IQR, lower whisker as the largest between minimum × value and Q1 – 1.5*IQR, and log 10 (geometric mean(MFI)) (diamond). Non-parametric tests were used to compare levels with or without clinical malaria (NM vs. M). p -values were adjusted for multiple comparisons, but none was significant. Only p -values

Techniques Used: Whisker Assay

Immunogenicity for CSP NANP stratified by previous clinical malaria: total IgG, IgG1-4 subclasses and IgM at month (M)20, 21, and 32 for RTS,S/AS01 vaccinees with (R3R) and without (R3C) booster, and comparator (C3C). Stratified analysis by malaria cases before M20, subjects who presented with clinical malaria (M = blue) and subjects without malaria (NM = red). Boxplots with medians, interquartile ranges (IQR), upper whisker as the smallest between maximum × value and Q3 + 1.5*IQR, lower whisker as the largest between minimum × value and Q1 – 1.5*IQR, and log 10 (geometric mean(MFI)) (diamond). Non-parametric tests were used to compare levels with or without clinical malaria (M vs. NM). p -values were adjusted for multiple comparisons, but none was significant. Only p -values
Figure Legend Snippet: Immunogenicity for CSP NANP stratified by previous clinical malaria: total IgG, IgG1-4 subclasses and IgM at month (M)20, 21, and 32 for RTS,S/AS01 vaccinees with (R3R) and without (R3C) booster, and comparator (C3C). Stratified analysis by malaria cases before M20, subjects who presented with clinical malaria (M = blue) and subjects without malaria (NM = red). Boxplots with medians, interquartile ranges (IQR), upper whisker as the smallest between maximum × value and Q3 + 1.5*IQR, lower whisker as the largest between minimum × value and Q1 – 1.5*IQR, and log 10 (geometric mean(MFI)) (diamond). Non-parametric tests were used to compare levels with or without clinical malaria (M vs. NM). p -values were adjusted for multiple comparisons, but none was significant. Only p -values

Techniques Used: Whisker Assay

Antibody responses against the blood stage antigen Rh5 for months (M) 0, 3, 20, 21, and 32 for IgG, IgG1, IgG2, IgG3, IgG4 and IgM. Boxplots with median, interquartile ranges (IQR), upper whisker as the smallest between maximum × value and Q3 + 1.5*IQR and lower whisker as the largest between minimum × value and Q1 – 1.5*IQR. The y -axis is in logarithm 10 scale. Data from months 0 and 3 were obtained from a previous study in the same individuals [7], thus a batch effect might be present. R3R (green): three doses of RTS,S/AS01 E and a RTS,S/AS01 E booster at month 20. R3C (red): three doses of RTS,S/AS01 E and a comparator booster. C3C (blue): three doses of a comparator vaccine and a comparator booster.
Figure Legend Snippet: Antibody responses against the blood stage antigen Rh5 for months (M) 0, 3, 20, 21, and 32 for IgG, IgG1, IgG2, IgG3, IgG4 and IgM. Boxplots with median, interquartile ranges (IQR), upper whisker as the smallest between maximum × value and Q3 + 1.5*IQR and lower whisker as the largest between minimum × value and Q1 – 1.5*IQR. The y -axis is in logarithm 10 scale. Data from months 0 and 3 were obtained from a previous study in the same individuals [7], thus a batch effect might be present. R3R (green): three doses of RTS,S/AS01 E and a RTS,S/AS01 E booster at month 20. R3C (red): three doses of RTS,S/AS01 E and a comparator booster. C3C (blue): three doses of a comparator vaccine and a comparator booster.

Techniques Used: Whisker Assay

Antibody responses against vaccine antigens for months (M) 0, 3, 20, 21, and 32 for IgG, IgG1, and IgG2. Boxplots with median, interquartile ranges (IQR), upper whisker as the smallest between maximum × value and Q3 + 1.5*IQR, and lower whisker as the largest between minimum × value and Q1 – 1.5*IQR. The y -axis is in logarithm 10 scale. Data from months 0 and 3 were obtained from a previous study in the same individuals 7 , thus a batch effect might be present. R3R (green): three doses of RTS,S/AS01 E and a RTS,S/AS01 E booster at month 20. R3C (red): three doses of RTS,S/AS01 E and a comparator booster. C3C (blue): three doses of a comparator vaccine and a comparator booster.
Figure Legend Snippet: Antibody responses against vaccine antigens for months (M) 0, 3, 20, 21, and 32 for IgG, IgG1, and IgG2. Boxplots with median, interquartile ranges (IQR), upper whisker as the smallest between maximum × value and Q3 + 1.5*IQR, and lower whisker as the largest between minimum × value and Q1 – 1.5*IQR. The y -axis is in logarithm 10 scale. Data from months 0 and 3 were obtained from a previous study in the same individuals 7 , thus a batch effect might be present. R3R (green): three doses of RTS,S/AS01 E and a RTS,S/AS01 E booster at month 20. R3C (red): three doses of RTS,S/AS01 E and a comparator booster. C3C (blue): three doses of a comparator vaccine and a comparator booster.

Techniques Used: Whisker Assay

RTS,S/AS01 E booster and long-term immunogenicity against vaccine antigens: total IgG, IgG1-2 subclasses for CSP constructs and HBsAg at month (M) 20, 21, and 32 for RTS,S/AS01 vaccinees with (R3R) and without (R3C) booster, and comparator (C3C). Boxplots with medians, interquartile ranges (IQR), upper whisker as the smallest between maximum × value and Q3 + 1.5*IQR, lower whisker as the largest between minimum × value and Q1 – 1.5*IQR, and log 10 (geometric mean(MFI)) (diamond). Non-parametric tests were used to compare the booster response (M20 vs. M21) and the long-term immunogenicity (M21 vs. M32), as well as to compare the R3C and R3R groups at each timepoint. Only p -values
Figure Legend Snippet: RTS,S/AS01 E booster and long-term immunogenicity against vaccine antigens: total IgG, IgG1-2 subclasses for CSP constructs and HBsAg at month (M) 20, 21, and 32 for RTS,S/AS01 vaccinees with (R3R) and without (R3C) booster, and comparator (C3C). Boxplots with medians, interquartile ranges (IQR), upper whisker as the smallest between maximum × value and Q3 + 1.5*IQR, lower whisker as the largest between minimum × value and Q1 – 1.5*IQR, and log 10 (geometric mean(MFI)) (diamond). Non-parametric tests were used to compare the booster response (M20 vs. M21) and the long-term immunogenicity (M21 vs. M32), as well as to compare the R3C and R3R groups at each timepoint. Only p -values

Techniques Used: Construct, Whisker Assay

RTS,S/AS01 E booster and long-term immunogenicity against vaccine antigens: IgG3-4 subclasses and IgM for CSP constructs and HBsAg at month (M) 20, 21, and 32 for RTS,S/AS01 vaccinees with (R3R) and without (R3C) booster, and comparator (C3C). Boxplots with medians, interquartile ranges (IQR), upper whisker as the smallest between maximum × value and Q3 + 1.5*IQR, lower whisker as the largest between minimum × value and Q1 – 1.5*IQR, and log 10 (geometric mean(MFI)) (diamond). Non-parametric tests were used to compare the booster response (M20 vs. M21) and the long-term immunogenicity (M21 vs. M32), as well as to compare the R3C and R3R groups at each timepoint. Only p -values
Figure Legend Snippet: RTS,S/AS01 E booster and long-term immunogenicity against vaccine antigens: IgG3-4 subclasses and IgM for CSP constructs and HBsAg at month (M) 20, 21, and 32 for RTS,S/AS01 vaccinees with (R3R) and without (R3C) booster, and comparator (C3C). Boxplots with medians, interquartile ranges (IQR), upper whisker as the smallest between maximum × value and Q3 + 1.5*IQR, lower whisker as the largest between minimum × value and Q1 – 1.5*IQR, and log 10 (geometric mean(MFI)) (diamond). Non-parametric tests were used to compare the booster response (M20 vs. M21) and the long-term immunogenicity (M21 vs. M32), as well as to compare the R3C and R3R groups at each timepoint. Only p -values

Techniques Used: Construct, Whisker Assay

RTS,S/AS01 E booster and long-term immunogenicity against the blood stage antigen Rh5: total IgG, IgG1-4 subclasses and IgM at month (M) 20, 21, and 32 for RTS,S/AS01 vaccinees with (R3R) and without (R3C) booster, and comparator (C3C). Boxplots with medians, interquartile ranges (IQR), upper whisker as the smallest between maximum × value and Q3 + 1.5*IQR, lower whisker as the largest between minimum × value and Q1 – 1.5*IQR, and log 10 (geometric mean(MFI)) (diamond). Non-parametric tests were used to compare the booster response (M20 vs. M21) and the long-term immunogenicity (M21 vs. M32), as well as to compare the R3C and R3R groups at each timepoint. Only p -values
Figure Legend Snippet: RTS,S/AS01 E booster and long-term immunogenicity against the blood stage antigen Rh5: total IgG, IgG1-4 subclasses and IgM at month (M) 20, 21, and 32 for RTS,S/AS01 vaccinees with (R3R) and without (R3C) booster, and comparator (C3C). Boxplots with medians, interquartile ranges (IQR), upper whisker as the smallest between maximum × value and Q3 + 1.5*IQR, lower whisker as the largest between minimum × value and Q1 – 1.5*IQR, and log 10 (geometric mean(MFI)) (diamond). Non-parametric tests were used to compare the booster response (M20 vs. M21) and the long-term immunogenicity (M21 vs. M32), as well as to compare the R3C and R3R groups at each timepoint. Only p -values

Techniques Used: Whisker Assay

Antibody responses against vaccine antigens for months (M) 0, 3, 20, 21, and 32 for IgG3, IgG4 and IgM. Boxplots with median, interquartile ranges (IQR), upper whisker as the smallest between maximum × value and Q3 + 1.5*IQR, and lower whisker as the largest between minimum × value and Q1 – 1.5*IQR. The y -axis is in logarithm 10 scale. Data from months 0 and 3 were obtained from a previous study in the same individuals [7], thus a batch effect might be present. R3R (green): three doses of RTS,S/AS01 E and a RTS,S/AS01 E booster at month 20. R3C (red): three doses of RTS,S/AS01 E and a comparator booster. C3C (blue): three doses of a comparator vaccine and a comparator booster.
Figure Legend Snippet: Antibody responses against vaccine antigens for months (M) 0, 3, 20, 21, and 32 for IgG3, IgG4 and IgM. Boxplots with median, interquartile ranges (IQR), upper whisker as the smallest between maximum × value and Q3 + 1.5*IQR, and lower whisker as the largest between minimum × value and Q1 – 1.5*IQR. The y -axis is in logarithm 10 scale. Data from months 0 and 3 were obtained from a previous study in the same individuals [7], thus a batch effect might be present. R3R (green): three doses of RTS,S/AS01 E and a RTS,S/AS01 E booster at month 20. R3C (red): three doses of RTS,S/AS01 E and a comparator booster. C3C (blue): three doses of a comparator vaccine and a comparator booster.

Techniques Used: Whisker Assay

Immunogenicity for CSP C-term stratified by previous clinical malaria: total IgG, IgG1-4 subclasses and IgM at month (M)20, 21, and 32 for RTS,S/AS01 vaccinees with (R3R) and without (R3C) booster, and comparator (C3C). Stratified analysis by malaria cases before M20, subjects who presented with clinical malaria (M = blue) and subjects without malaria (NM = red). Boxplots with medians, interquartile ranges (IQR), upper whisker as the smallest between maximum × value and Q3 + 1.5*IQR, lower whisker as the largest between minimum × value and Q1 – 1.5*IQR, and log 10 (geometric mean(MFI)) (diamond). Non-parametric tests were used to compare levels with or without clinical malaria (M vs. NM). p -values were adjusted for multiple comparisons, but none was significant. Only p -values
Figure Legend Snippet: Immunogenicity for CSP C-term stratified by previous clinical malaria: total IgG, IgG1-4 subclasses and IgM at month (M)20, 21, and 32 for RTS,S/AS01 vaccinees with (R3R) and without (R3C) booster, and comparator (C3C). Stratified analysis by malaria cases before M20, subjects who presented with clinical malaria (M = blue) and subjects without malaria (NM = red). Boxplots with medians, interquartile ranges (IQR), upper whisker as the smallest between maximum × value and Q3 + 1.5*IQR, lower whisker as the largest between minimum × value and Q1 – 1.5*IQR, and log 10 (geometric mean(MFI)) (diamond). Non-parametric tests were used to compare levels with or without clinical malaria (M vs. NM). p -values were adjusted for multiple comparisons, but none was significant. Only p -values

Techniques Used: Whisker Assay

40) Product Images from "Association of immunoglobulin G4 and free light chain with idiopathic pleural effusion"

Article Title: Association of immunoglobulin G4 and free light chain with idiopathic pleural effusion

Journal: Clinical and Experimental Immunology

doi: 10.1111/cei.12999

Correlation of the effusion κ/λ free L chains (FLC) ratio with immunoglobulin (Ig)G4 + plasma cell counts (a) and IgG4 + /IgG + plasma cell ratio (b) in the pleura of patients in the IgG4 + group. *One‐tailed P ‐value.
Figure Legend Snippet: Correlation of the effusion κ/λ free L chains (FLC) ratio with immunoglobulin (Ig)G4 + plasma cell counts (a) and IgG4 + /IgG + plasma cell ratio (b) in the pleura of patients in the IgG4 + group. *One‐tailed P ‐value.

Techniques Used: One-tailed Test

Receiver operating characteristic (ROC) analysis on diagnostic utility of immunoglobulin (Ig)G4 and κ/λ ratio for distinguishing patients between the IgG4 − and IgG + groups. Cut‐off value for κ/λ ratio, 1·42; sensitivity, 0·87; specificity, 0·83. Area under the curve (AUC), 0·88; 95% confidence interval (CI) for the AUC, 0·74 – 1·00. Cut‐off value for IgG4/IgG ratio, 2·75%; sensitivity, 0·75; specificity, 0·74; AUC, 0·80; 95% CI for the AUC, 0·66–0·94.
Figure Legend Snippet: Receiver operating characteristic (ROC) analysis on diagnostic utility of immunoglobulin (Ig)G4 and κ/λ ratio for distinguishing patients between the IgG4 − and IgG + groups. Cut‐off value for κ/λ ratio, 1·42; sensitivity, 0·87; specificity, 0·83. Area under the curve (AUC), 0·88; 95% confidence interval (CI) for the AUC, 0·74 – 1·00. Cut‐off value for IgG4/IgG ratio, 2·75%; sensitivity, 0·75; specificity, 0·74; AUC, 0·80; 95% CI for the AUC, 0·66–0·94.

Techniques Used: Diagnostic Assay

Comparison of pleural fluid levels of the κ and λ free L chains (FLC) (a,b) and κ/λ ratio (c). Median and interquartile ranges are shown. (−), Immunoglobulin (Ig)G4 − group; (+), IgG4 + group.
Figure Legend Snippet: Comparison of pleural fluid levels of the κ and λ free L chains (FLC) (a,b) and κ/λ ratio (c). Median and interquartile ranges are shown. (−), Immunoglobulin (Ig)G4 − group; (+), IgG4 + group.

Techniques Used:

Comparison of pleural fluid levels of immunoglobulins between the immunoglobulin (Ig)G4 − and IgG4 + groups. (−), IgG4 − group; (+), IgG4 + group. Median and interquartile ranges are shown.
Figure Legend Snippet: Comparison of pleural fluid levels of immunoglobulins between the immunoglobulin (Ig)G4 − and IgG4 + groups. (−), IgG4 − group; (+), IgG4 + group. Median and interquartile ranges are shown.

Techniques Used:

Analysis of the clonality of the effusion immunoglobulin (Ig)G4 antibodies of patients in the IgG4 + group by two‐dimensional electrophoresis (2‐DE). Control IgG4 κ myeloma protein from Sigma (cat no. I4639) (a –c). Effusion IgG4 antibodies of representative cases with abnormal IgG4 levels (d–i). The H and L chains were probed with anti‐IgG4‐Fc (left), anti‐κ chain (middle) and anti‐λ chain (right) antibodies.
Figure Legend Snippet: Analysis of the clonality of the effusion immunoglobulin (Ig)G4 antibodies of patients in the IgG4 + group by two‐dimensional electrophoresis (2‐DE). Control IgG4 κ myeloma protein from Sigma (cat no. I4639) (a –c). Effusion IgG4 antibodies of representative cases with abnormal IgG4 levels (d–i). The H and L chains were probed with anti‐IgG4‐Fc (left), anti‐κ chain (middle) and anti‐λ chain (right) antibodies.

Techniques Used: Electrophoresis

Related Articles

Produced:

Article Title: The in Vitro Antigenicity of Plasmodium vivax Rhoptry Neck Protein 2 (PvRON2) B- and T-Epitopes Selected by HLA-DRB1 Binding Profile
Article Snippet: .. A 1:1,000 dilution of monoclonal anti-human IgG1–biotin antibody produced in mouse (clone 8c/6-39), 1:15,000 monoclonal anti-human IgG2–biotin antibody produced in mouse (clone HP-6014), 1:40,000 monoclonal anti-human IgG3–biotin antibody produced in mouse (clone HP-6050) and 1:60,000 anti-human IgG4–biotin antibody, mouse monoclonal (clone HP-6025) (Sigma Aldrich) were used. .. ImmunoPure streptavidin, horseradish peroxidase conjugate (Thermo Scientific), at 1:5,000, dilution, was used as secondary antibody and TMB 2-Component Microwell peroxidase as substrate.

Article Title: Profiling of microorganism-binding serum antibody specificities in professional athletes
Article Snippet: .. For IgG subclass analysis, Biotin Mouse Anti-Human IgG1, IgG2, IgG4 (BD Biosciences, CA, USA), and Monoclonal Anti-Human IgG3-Biotin antibody produced in mouse (Sigma Aldrich) were used.All secondary antibodies were incubated for 1 hour at RT. .. After washing with PBS, streptavidin–horse radish peroxidase (Biolegend, San Diego, CA, USA) was added and incubated for 1 hour at RT.

Incubation:

Article Title: Profiling of microorganism-binding serum antibody specificities in professional athletes
Article Snippet: .. For IgG subclass analysis, Biotin Mouse Anti-Human IgG1, IgG2, IgG4 (BD Biosciences, CA, USA), and Monoclonal Anti-Human IgG3-Biotin antibody produced in mouse (Sigma Aldrich) were used.All secondary antibodies were incubated for 1 hour at RT. .. After washing with PBS, streptavidin–horse radish peroxidase (Biolegend, San Diego, CA, USA) was added and incubated for 1 hour at RT.

Article Title: Influence of camel milk on the hepatitis C virus burden of infected patients
Article Snippet: .. After 1 h incubation at room temperature, the plates were washed five times, sequentially, with PBS and 50 µl biotin-labeled goat-antihuman IgG1 (1:1,000; cat. no. B6775), biotin-labeled goat-antihuman IgG2 (1:15,000; cat. no. B3398), biotin-labeled goat-antihuman IgG3 (1:4,000; cat. no. B3523), or biotin-labeled goat-antihuman IgG4 (1:15,000; cat. no. B3648; Sigma-Aldrich; Merck Millipore, Darmstadt, Germany) were added. .. The plates were washed five times to remove unbound antibodies and 50 µl streptavidin-alkaline phosphatase-conjugate (Sigma-Aldrich; Merck Millipore) diluted 1:4,000 with 2% BSA-PBS was subsequently added.

Article Title: Distinct Autoimmune Anti-α-Synuclein Antibody Patterns in Multiple System Atrophy and Parkinson’s Disease
Article Snippet: .. For IgG4 assays, plasma samples were diluted 1:50. (4) After a subsequent washing step, the plates were incubated at RT for 2 h with 50 μl of biotinylated secondary antibodies at the following concentrations: goat anti-human total IgG 1:30,000 (Sigma-Aldrich, cat# SAB3701279, RRID:AB_2783655 ), goat anti-human IgM (1:5,000; Sigma-Aldrich, cat# B1265, RRID:AB_258514 ), mouse anti-human IgG1 (1:1,000; Thermo Fisher Scientific, Cat# MH1515, RRID:AB_2539710 ), mouse anti-human IgG2 (1:5,000: Sigma-Aldrich, cat# B3398, RRID:AB_258546 ), mouse anti-human IgG3 (1:500; Sigma-Aldrich, cat# B3523, RRID:AB_258549 ), and mouse anti-human IgG4 (1:200; Sigma-Aldrich, cat# B3648, RRID:AB_258555 ). .. After washing, 50 μl portions of streptavidin-peroxidase (1:10,000; Sigma-Aldrich, cat# 5512) were added to each well and incubated for 30 min at RT. (5) The plates were washed for the last time before the enzymatic reaction was developed by adding 50 μl of tetramethylbenzidine (TMB) Liquid Peroxidase Substrate (Sigma-Aldrich, cat# T8665) and incubated in dark for 30 min at RT. (6) The enzymatic reaction was terminated by addition of 0.5 N Sulfuric Acid (Merck, cat# 109073), and (7) the optical density (OD) was measured on a MultiscanTM FC Microplate reader (Fisher ScientificTM ) at 450/620 nm.

Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94
    Millipore human igg4
    Generation and validation of human CLEC9A‐WT1 and DEC‐205‐WT1 vaccines. (a) Diagram of a chimeric Ab comprising rat or mouse variable regions specific for human CLEC9A, human DEC‐205, or bacterial β‐galactosidase (β‐gal), and human <t>IgG4</t> and κ constant regions genetically fused to an antigenic sequence from WT1 containing the HLA‐A*201‐restricted WT1 126–134 (RMFPNAPYL) and HLA‐A*2402‐restricted WT1 235–243 (CMTWNQMNL) epitopes, a pan‐MHC II epitope (KLSHLQMHSRKH), and a FLAG tag. (b) Flow cytometric analysis of CLEC9A‐WT1 (white, left panels), DEC‐205‐WT1 (white, right panels) and control‐WT1 (grey, control) binding to human PBMCs. Data are representative of three healthy blood donors.
    Human Igg4, supplied by Millipore, used in various techniques. Bioz Stars score: 94/100, based on 10 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human igg4/product/Millipore
    Average 94 stars, based on 10 article reviews
    Price from $9.99 to $1999.99
    human igg4 - by Bioz Stars, 2020-08
    94/100 stars
      Buy from Supplier

    85
    Millipore murine biotinylated mab 15 2
    Generation and validation of human CLEC9A‐WT1 and DEC‐205‐WT1 vaccines. (a) Diagram of a chimeric Ab comprising rat or mouse variable regions specific for human CLEC9A, human DEC‐205, or bacterial β‐galactosidase (β‐gal), and human <t>IgG4</t> and κ constant regions genetically fused to an antigenic sequence from WT1 containing the HLA‐A*201‐restricted WT1 126–134 (RMFPNAPYL) and HLA‐A*2402‐restricted WT1 235–243 (CMTWNQMNL) epitopes, a pan‐MHC II epitope (KLSHLQMHSRKH), and a FLAG tag. (b) Flow cytometric analysis of CLEC9A‐WT1 (white, left panels), DEC‐205‐WT1 (white, right panels) and control‐WT1 (grey, control) binding to human PBMCs. Data are representative of three healthy blood donors.
    Murine Biotinylated Mab 15 2, supplied by Millipore, used in various techniques. Bioz Stars score: 85/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/murine biotinylated mab 15 2/product/Millipore
    Average 85 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    murine biotinylated mab 15 2 - by Bioz Stars, 2020-08
    85/100 stars
      Buy from Supplier

    94
    Millipore flow cytometry fc analysis
    Generation and validation of human CLEC9A‐WT1 and DEC‐205‐WT1 vaccines. (a) Diagram of a chimeric Ab comprising rat or mouse variable regions specific for human CLEC9A, human DEC‐205, or bacterial β‐galactosidase (β‐gal), and human <t>IgG4</t> and κ constant regions genetically fused to an antigenic sequence from WT1 containing the HLA‐A*201‐restricted WT1 126–134 (RMFPNAPYL) and HLA‐A*2402‐restricted WT1 235–243 (CMTWNQMNL) epitopes, a pan‐MHC II epitope (KLSHLQMHSRKH), and a FLAG tag. (b) Flow cytometric analysis of CLEC9A‐WT1 (white, left panels), DEC‐205‐WT1 (white, right panels) and control‐WT1 (grey, control) binding to human PBMCs. Data are representative of three healthy blood donors.
    Flow Cytometry Fc Analysis, supplied by Millipore, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/flow cytometry fc analysis/product/Millipore
    Average 94 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    flow cytometry fc analysis - by Bioz Stars, 2020-08
    94/100 stars
      Buy from Supplier

    Image Search Results


    Generation and validation of human CLEC9A‐WT1 and DEC‐205‐WT1 vaccines. (a) Diagram of a chimeric Ab comprising rat or mouse variable regions specific for human CLEC9A, human DEC‐205, or bacterial β‐galactosidase (β‐gal), and human IgG4 and κ constant regions genetically fused to an antigenic sequence from WT1 containing the HLA‐A*201‐restricted WT1 126–134 (RMFPNAPYL) and HLA‐A*2402‐restricted WT1 235–243 (CMTWNQMNL) epitopes, a pan‐MHC II epitope (KLSHLQMHSRKH), and a FLAG tag. (b) Flow cytometric analysis of CLEC9A‐WT1 (white, left panels), DEC‐205‐WT1 (white, right panels) and control‐WT1 (grey, control) binding to human PBMCs. Data are representative of three healthy blood donors.

    Journal: Clinical & Translational Immunology

    Article Title: Human CLEC9A antibodies deliver Wilms' tumor 1 (WT1) antigen to CD141+ dendritic cells to activate naïve and memory WT1‐specific CD8+ T cells

    doi: 10.1002/cti2.1141

    Figure Lengend Snippet: Generation and validation of human CLEC9A‐WT1 and DEC‐205‐WT1 vaccines. (a) Diagram of a chimeric Ab comprising rat or mouse variable regions specific for human CLEC9A, human DEC‐205, or bacterial β‐galactosidase (β‐gal), and human IgG4 and κ constant regions genetically fused to an antigenic sequence from WT1 containing the HLA‐A*201‐restricted WT1 126–134 (RMFPNAPYL) and HLA‐A*2402‐restricted WT1 235–243 (CMTWNQMNL) epitopes, a pan‐MHC II epitope (KLSHLQMHSRKH), and a FLAG tag. (b) Flow cytometric analysis of CLEC9A‐WT1 (white, left panels), DEC‐205‐WT1 (white, right panels) and control‐WT1 (grey, control) binding to human PBMCs. Data are representative of three healthy blood donors.

    Article Snippet: Generation and validation of human CLEC9A‐WT1 and DEC‐205‐WT1 vaccines Expression constructs were generated in pcDNA3.1+ plasmids encoding the human IgG4 and κ constant regions and the variable regions of rat anti‐human CLEC9A clone 4C6, mouse anti‐human DEC‐205 clone MMRI‐7, or rat anti‐bacterial β‐galactosidase (β‐gal) clone GL117.

    Techniques: Sequencing, FLAG-tag, Binding Assay